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INTRODUCTION
A century after the rediscovery of Mendel's law and the publication of Boveri’s theory of aberrant
chromosomes  in  the  origin  of  cancer  in  1914,  cancer  researchers  are  now  able  to  trace  historical
landmarks in the development of cancer genetics. The discovery of oncogenes and tumour suppressor
genes took place in the 1980s, and more recently, the sequence for the human genome was completed in
2003 (Balmain 2003; Knudson 2001). The many stimulatory "oncogenes" and inhibitory "tumour
suppresser genes" that were identified in human neoplasms in the last decades have greatly increased
our understanding of the complexity not only of tumourigenesis but also of normal  growth regulatory
pathways in different human cell types (Macleod 2000, Nowell 2002). Increasing molecular knowledge
has provided a large window of opportunity for both diagnostic and therapeutic purposes (Vogelstein and
Kinzler 2004; Vescovi et al. 2006).
The von Hippel Lindau (VHL) disease is a rare, autosomal dominantly inherited disorder which
predisposes  patients to develop a variety of benign or malignant tumours in different organs, capillary
hemangioblastomas (CHB) of the central nervous system (CNS) and retina, renal cell carcinoma (RCC),
pheochromocytoma (PCC), pancreatic and endolymphatic cysts. It is believed that the loss or inactivation
of the VHL gene which is located at 3p25-26 is responsible for the development of these tumours (Gallou
et al. 2004; Kaelin 2007). CHBs are highly vascular benign tumours of the CNS, accounting for 1 - 2.5%
of  all  intracranial  neoplasms  (Böhling  et  al.  2000;  Zbar  et  al.  1999).  They  occur  either  as  a  sporadic
entity or as part  of  VHL disease (Bahig et  al.  2008; Neumann and Bender 1998).  In fact,  they are the
most common manifestations of VHL disease, affecting 60 - 80% of VHL patients. CHB may be single and
the only manifestation of the VHL disease, but there are often multiple manifestations in patients with
VHL. This disease can strike at virtually any age, from 11 to 71 years (Choyke et al. 1995; Maher 2004).
Recently, it was possible to detect a 100% mutation rate in familial cases (Stolle et al. 1998). However,
in about half of the sporadic cases, it is possible to demonstrate the inactivation of  the VHL gene (Bahig
et al. 2008; Gläsker et al. 2001; Kanno et al. 1994).
PCC is a rare neuroendocrine tumour of the chromaffin cells that contain catecholamine-containing
neurosecretory granules. (Koch et al. 2001). Multiple genetic alterations have been associated with PCC.
Most PCCs are sporadic, but they also occur in inherited tumour syndromes. A familial predisposition is
seen in patients with VHL disease (Pacak et al. 2001), multiple endocrine neoplasia type II (MEN II) and
neurofibromatosis type 1 (NF1), (Brandi et al. 2001; Walther et al. 1999). It has been estimated that
10% of PCCs are familial cases; however, recent studies indicate that this percentage could be as high as
24% (Neumann et al.  2002).  PCC occurs in between 10 to 34% of VHL patients (Walther et  al.  1999,
Maher et al. 1990b; Richard et al. 1994).
The purpose of the present work was to search for genetic alterations, or other mechanisms of
inactivation, in addition to the VHL gene, that may be important in the development of VHL-associated
tumours. Though less dramatic than cure, prevention and early detection are the most promising and
feasible means to reduce cancer morbidity and mortality (Vogelstein and Kinzler 2004). This thesis work
is based on the view that increasing knowledge on the molecular events underlying tumour development
will eventually aid in early detection and in that way lead to improved treatment.
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REVIEW OF THE LITERATURE
Tumourigenesis
Tumour growth
Tumour is an abnormal growth resulting from uncontrolled, progressive multiplication of cells, serving no
physiological function. A tumour may be benign or malignant (Komarova et al. 2003). The major
characteristic that differentiates malignant tumours from the benign counterparts is their invasiveness.
The  cells  in  malignant  tumours  differ  from  benign  tumour  cells  in  many  ways,  at  least  three  to  five
mutations are required to develop a malignant solid tumour; in contrast only one or two mutations may
be needed on the road to a benign tumour (Nowell 2002).
Several lines of evidence indicate that tumourigenesis in humans is a multistep process and that
these steps reflect genetic alterations that drive the progressive transformation of a normal human cell
into becoming a highly malignant tumour (Hanahan and Weinberg 2000; Knudson 2002; Renan 1993).  It
has been suggested that the vast catalogue of cancer cell genotypes is a manifestation of six essential
alterations in cell physiology that collectively dictate malignant growth;  self sufficiency in growth signals,
insensitivity to growth inhibitory (antigrowth ) signals, evasion of programmed cell death (apoptosis),
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan and
Weinberg 2000).
Oncogenes, tumour suppressor and stability or caretaker genes
Cell proliferation is regulated through connected molecular pathways controlling cell division,
differentiation, growth arrest, and apoptosis. Tight control of these events is necessary for the
maintenance of homeostasis and involves multiple genes. Deregulation of some of these genes can lead
to pathological situations as well as to malignancy.  Alterations caused by somatic or germ-line mutations
in proto-oncogenes, tumour suppressor genes and stability genes are responsible for tumourigenesis
(Vogelstein and Kinzler 2004). After it has mutated, a proto-oncogene becomes activated and this results
in a "gain of function" i.e. it becomes an oncogene.
Oncogenic activation can be a result of chromosomal translocations, gene amplifications or from
subtle  intragenic  mutations  affecting  crucial  residues  that  regulate  the  activity  of  the  gene  product
(Balmain 2001; Knudson 1985; Rowley 1983). An activating somatic mutation in one allele of an
oncogene is generally sufficient (dominant) to confer a selective growth advantage on the cell.  Examples
of oncogenes include the MET gene which predisposes to hereditary papillary renal cell carcinoma, and
the RET gene which is involved in multiple endocrine neoplasia II. Mutations in K-ras gene occur in lung,
ovarian and bladder carcinoma, the N-ras gene mutations are frequent in head and neck cancers
(Vogelstein and Kinzler 2004).
Tumour suppressor genes (TSG) are targeted in the opposite way by genetic alterations; mutations
reduce or abolish the activity of the gene product, thus causing loss of their functions (Knudson 2002;
Vogelstein and Kinzler 2004). This kind of inactivation can arise from missense mutations at locations
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that are essential for the protein activity, frame-shift mutations that result in a truncated protein, from
deletions or insertions of various sizes, or from epigenetic silencing of the gene. Mutations in other
genetic  (even  epigenetic)  alterations  affecting  both  the  maternal  and  paternal  alleles  of  a  TSG  are
generally  required  in  order  to  confer  a  selective  advantage  to  the  cell.  Such  a  condition  may  arise
through the deletion of one allele via a gross chromosomal event - such as the loss of an entire
chromosome or chromosome arm or loss of heterozygosity coupled with an intragenic mutation of the
other allele (Elias 1998; Knudson 2002).
A third class of cancer genes called stability genes or caretakers which promote tumourigenesis in a
completely  different  way  when  mutated.  This  group  includes  the  mismatch  repair  (MMR), nucleotide-
excision repair (NER)  and  base-excision  repair  (BER) genes which are responsible for repairing subtle
mistakes made during normal DNA replication or those errors induced by exposure to mutagens. Other
instability genes regulate the process involving large portions of chromosomes, such as those responsible
for mitotic recombination and chromosomal segregation (Friedberg 2003; Lengauer et al. 1998; Robert
2007b). The XPA and XPC genes  for  xeroderma  pigmentosum,  as  well  as  the MSH2 gene for human
nonpolyposis colon cancer (HNPCC), are examples of genomic instability genes.
For many years, many investigators have indicated the importance of genetic instability in the clonal
evolution of tumour cells and related clinical progression of tumours. However, only a recent profusion of
tumourigenic models and discussion articles has led to a higher profile for the debate about the role of
genomic instability in tumourigenesis (Sieber et al. 2005). It is now widely accepted that cancer results
from the accumulation of mutations in the genes that directly control cell division. However the
mechanisms by which these mutations are generated have been the subject of continuing debate. It has
been argued that an existing genetic instability is absolutely required for the generation of the multiple
mutations that underlie cancer (Lengauer et al. 1998).
Cellular DNA is under constant attack from a variety of sources, including chemicals, ionizing
radiation, heat, tumour-inducing viruses, enzymatic errors etc. However genomic stability is maintained
by  the  efficient  repair  of  damage  to  the  bases  present  in  DNA.  The  stability  genes  keep  genetic
alterations to a minimum, and thus, when they became inactivated, mutations in other genes occur at a
higher  rate  (Elias  1998;  Friedberg  2003).  All  genes  are  potentially  affected  by  the  resultant  increased
rate of mutations but only mutations in oncogenes and tumour-suppressor genes influence the net cell
growth and can thereby confer a selective growth advantage onto the mutant cell (Vogelstein and Kinzler
2004).
Familial or inherited cancer syndromes
The  past  decade  has  witnessed  the  elucidation  of  the  specific  genetic  bases  of  numerious  inherited
predispositions. Hereditary cancer syndromes comprise approximately 5 - 10% of diagnosed carcinomas.
They are caused by mutations in specific genes; carriers of mutations in these genes are at an increased
risk of developing cancer at young age (Apessos et al. 2008).
The identification of susceptibility genes for specific types of cancer provided the necessary information
for the complete characterization of inherited cancer syndromes. The close observation of carrier families
has significantly enriched our knowledge on distinct phenotypical features, age of onset and survival rates
for each syndrome, and provide the possibility to further understand the molecular bases of hereditary
cancer (Eng et al. 2001; Fostira et al 2007).
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Significance of genetic alterations
In 1914, Theodor Boveri first hypothesised that tumour growth is based on a particular, incorrect
chromosome combination which is the cause of the abnormal growth characteristics passed on to
daughter cells (reviewed in (Balmain 2001). More than half a century later, in 1971, Knudson and co-
workers carried out an epidemiological study on retinoblastoma and postulated that "two hits" are
required  for  the  complete  inactivation  of  a  TSG,  suggesting  that  cancer  predisposition  results  from
inheritance of a specific mutation in a suppressor gene, but that the development of tumours requires
subsequent somatic alterations that causes loss of the wild type copy of the same gene (Knudson 1971).
Examples of TSG include the TP53 gene, which is mutated in more than 50% of human cancers; the RB1
gene that predisposes to retinoblastoma; VHL gene that is involved capillary hemangioblastoma (CHB),
Renal cell carcinoma (RCC), pheochromocytoma (PCC), the BRCA1 and BRCA2 genes  that  confer
susceptibility towards breast and ovarian cancer, and the NF1 gene, predisposing to neurofibromas
(Vogelstein and Kinzler 2004).
Additionally, chronic inflammation has been proposed as a risk factor for a variety of epithelial
cancers. An inflammatory response, accompanied by the generation of free radicals, is capable of both
directly damaging DNA and enhancing the genetic instability of the affected cells (Dobrovolskaia and
Kozlov 2005).
Epigenetic mechanisms and promoter hypermethylation
Interestingly, in addition to the extensively studied current dogma that cancer is predominantly a genetic
disease, recent data have also highlighted the contribution of epigenetic events (Baylin et al. 2000).
Heritable changes that do not depend on changes in the DNA sequence but rather on the pattern of gene
expression are called epigenetic changes. They may affect the expression of the gene or the properties of
its product (Read and Strachan 1999). This change in gene expression involves the methylation of DNA in
promoter regions of the genes. DNA methylation is a crucial epigenetic modification of the genome that is
involved in regulating many cellular processes, including genomic imprinting and chromosome stability
(Robertson 2005). Changes in methylation patterns in the promoter regions of crucial genes can alter
gene expression. Since the methylation rate is thought to be faster than the genetic mutation rate,
epigenetic alterations may be more likely to initiate neoplasms rather than genetic mutations (Baylin et
al. 2000) Epigenetic changes, such as aberrant promoter methylation and loss of imprinting, have been
identified as early and ubiquitous alterations in human cancer. Promoter hypermethylation of tumour
suppressor genes is recognized as an alternative to genetic alterations in disrupting gene function. They
can also be tissue- and tumour-type specific (Belinsky  2004;  Feinberg  et  al.  2006;  Jones  and  Baylin
2002).
In tumour suppressor gene inactivation, genetic and epigenetic mechanisms may act in parallel; bi-
allelic inactivation may occur via a combination of mutational and epigenetic events, following the
principle of the Knudson two-hit hypothesis of tumourigenesis (Jones and Laird 1999).
In the human genome, DNA methylation is restricted to cytosines of CpG (cytosine-phosphoguanine)
dinucleotides which are often clustered into CpG-rich regions known as CpG islands. CpG islands are
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defined as regions of the genome which are about 1kb long and are not only CpG rich, but generally G/C
rich as well. These islands are usually found at the 5` end of genes, the region often associated with sites
where the transcription of DNA into RNA begins i.e, the promoter region (Bird 1992; Laird and Jaenisch
1994; Laird 2005). In the bulk of the genome, about 80% of the CpG dinucleotides that are not
associated with CpG islands are heavily methylated. In contrast, the dinucleotides in CpG islands,
especially those associated with gene promoters, are usually unmethylated, whether or not the gene is
being transcribed (Bird 2002; James and Stephen 2003).
DNA molecules can be altered covalently by the attachment of methyl groups to cytosine bases, this
modification of genomic DNA can be as important as a mutation in shutting down tumour suppressor
genes. More specifically, when CpG methylation occurs in the vicinity of the gene promoter, it can cause
repression of  transcription of  the associated gene (Robert,  2007b). A growing number of cancer genes
that harbour dense methylation in normally unmethylated promoter CpG islands are becoming
recognised, this hypermethylation can contribute to loss of gene function.  In many tumours, it has been
discovered that the function of a tumour suppressor gene is abrogated by hypermethylation of the
promoter region, e.g VHL (renal cell carcinoma, capillary hemangioblastoma), BRCA1 (in  breast  and
ovarian cancer), 8P16 (in  most  lymphoma)  (Baylin  et  al.  2000;  Jones  and  Baylin  2002).  Properly
established and maintained DNA methylation patterns are essential for mammalian development and for
normal  functioning  of  the  adult  organism  (Mayer  et  al.  2000.;  Merlo  et  al.  2006;  Panning  B  1996;
Robertson 2005). Imprinted genes are particularly intriguing examples of epigenetic modification. Their
expression is controlled by patterns of methylation that differ according to the parental origin of the
gene. When either the imprinting mechanism malfunctions or the parental origin is not as expected, then
a pathogenic loss of function or inappropriate expression can occur in intact genes (Arima et al. 2005;
Read and Strachan 1999).
Molecular biology methods and research tools
Important advanced methods have been developed and used to clarify the puzzle of tumour formation
and growth. The development of cytogenetic methods was crucial in understanding chromosomal
aberrations as visualised by Boveri under the microscope (reviewed in (Balmain 2001). Subsequently,
multiple cytogenetic and molecular genetic methods have been developed. Comparative genomic
hybridization (CGH) was the first efficient approach for scanning the entire genome for variations in DNA
copy number. CGH is a powerful molecular cytogenetic method for detecting DNA sequence copy number
changes throughout the genome in tumors; it helps to analyze the total genome for loss or gain of
genetic material in a single experiment (Kallioniemi et al. 1992; Kallioniemi et al. 1994). Additional
methods such as flourescence in situ hybridization (FISH) can also be used to determine the copy number
associated with a given ratio level, and recently a further method development called Array CGH has
been implemented using a wide variety of  techniques (Pinkel and Albertson 2005). Array comparative
genomic hybridization (array CGH), is a method designed for identifying genomic regions with copy
number aberrations (Pinkel et al. 1998; Pinkel and Albertson 2005). The development of high density
arrays consisting of tens of thousands of DNA targets spanning the entire human genome has enabled
precision mapping of the boundaries of genetic alterations throughout the genome in a single experiment
(Barrett et al. 2004; Bignell et al. 2004).
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The cytogenic discovery of germ-line aberrations, together with the use of restriction fragment
length polymorphism (RFLPs), led to the cloning of several hereditary cancer genes (Knudson 2001).
Choromosomal locations commonly deleted in tumour cells can be characterised by loss of
heterozygosity. Inactivation (by mutation or methylation) of one copy of a TSG may be followed by other
mechanisms that facilitate loss of  the other gene copy. These mechanisms depend on LOH at the TSG
locus, and may involve mitotic recombination, loss of a choromosomal region that harbors the target
gene, inappropriate chromosomal segregation (nondisjunction), or loss of a more defined chromosomal
region. Repeated LOH occurring in a given chromosomal region in a number of independently arising
tumours often indicates the presence of a TSG in that region (Read and Strachan 1999; Weinberg 2007).
von Hippel-Lindau (VHL) disease and VHL-associated
tumours
History of the VHL disease
In 1872, the first reports of apparently cystic, neoplastic lesions involving several organs, particularly the
retina were published, describing angiomatous lesions of the retina, which were sometimes associated
with identical lesions in the cerebellum (Melmon 1964, Jakson 1872). However, in 1894, it was Treacher
Collins, who detailed his histological observations on bilateral lesions in the retinas and stated that the
site  of  the  lesions  was  in  the  vascular  structures.  He  was  the  first  to  have  access  to  tissues  from  a
brother and sister, and described the angiomatous nature of the retinal lesion (Collins 1894). In 1904 a
German ophthalmologist, von Hippel, presented clinical data gathered from two brothers. Unaware of
Collin's work and lacking tissue for study, at that time he was unable to assign a known cause to this
disease. However, seven years later, having obtained tissue from one of his patients and now being
aware  of  Collins'  work,  von  Hippel  concluded  that  the  primary  lesion  in  the  retina  was  a  tumour  and
called the disease "angiomatosis retinae" (von Hippel 1904).
Later, several case reports were published about the findings of angiomatous retinae in patients who
additonally suftured brain tumours and visceral lesions. Arvid Lindau, a Swedish pathologist from Lund,
was the first  to be credited with these critical  observations.  He collected the data on forty such cases,
twenty-four from the literature and sixteen of his own, and reviewed the literature on over 200 cases. In
his monograph in 1926, Lindau brought together into one coherent entity the retinal, cerebral, and
visceral components of this disease, and noted that the condition is heritable and used the term "Central
nervous system angiomatosis" (Lindau 1927). Lindau's findings were rapidly accepted by Cushing and
Bailey,  who  in  1928  re-named  the  vascular  central  nervous  system  (CNS)  tumours  as  capillary
hemangioblastoma (CHB) and used the eponym "Lindau's disease" (Cushing and Bailey 1928). Later
scattered clinical reports of families with several affected members confirmed the association of CHB of
CNS, renal and pancreatic cysts, pheochromocytomas (PCC), renal cell carcinomas (RCC) and epididymal
cytadenomas. In 1964 Melmon and Rosen summarized this data and described a large family with this
disease and codified the term "von Hippel-Lindau" (VHL) disease (Melmon and Rosen 1964).
REVIEW OF THE LITERATURE
____________________________________________________________________________________
13
The nosology of VHL disease has been extended through an improved understanding of the lesions
of  the  CNS,  delineation  of  renal  and  pancreatic  involvement,  and  the  associated  risk  of  PCCs,  e.g.  its
adrenal and extra-adrenal nature. Computed tomography (CT) and ultrasound (US) greatly helped in the
identification of affected members, and later, magnetic resonance image (MRI) became a key method for
screening cerebellum and spine (Fill et al. 1979; Jennings et al. 1988). Numerous cytogenetic and
molecular studies identified deletions of 3p as a hallmark of VHL tumours, but it was not until 1988 than
the gene was mapped to the short arm of chromosomal region 3p25-26 (Seizinger et al. 1988). Later, in
1993, the gene was isolated by positional cloning, then after many different germ-line and somatic VHL
mutations had been identified as causes of VHL disease, the gene was demonstrated to be a TSG (Latif et
al. 1993).
The identification of a pathogenic germ-line VHL gene mutation provides a specific and reliable basis
for  the diagnosis of VHL -disease. The key indications  for  the molecular  test are indicated in Table 1.
This has improved the diagnosis and clinical management of the disease, and also provided insights into
the pathogenesis of sporadic VHL-associated tumours (Maher 2004) (Table 1). However if molecular
diagnosis is not possible, less sensitive clinical diagnostic criteria need to be employed.  The clinical
diagnostic criteria for VHL disease were proposed by Melmon and Rosen (Melmon and Rosen 1964). Thus
if there is the presence of a confirmed family history of VHL disease, the finding of a single typical VHL
tumour in an at-risk relative enables a clinical diagnosis of VHL disease to be made. However, in isolated
cases without a family history, the presence of two or more CHBs or one CHB and visceral manifestations
are required for the diagnosis (Maher et al. 1991). Relatively few patients exhibit all the manifestations of
VHL disease. About 50% of VHL patients will only display one manifestation of the disease (Latif et al.
1993; Maher 2004).
The  onset  of  VHL  disease  is  variable  and  depends  on  the  expression  of  the  disease  within  the
individual and within the family and the intensity with which asymptomatic lesions are sought. It may
present in childhood or at  old age but the usual  age of  symptomatic presentation is  in the 2nd or 3rd
decades of life, and penetrance is considered to be complete by the age 60. Retinal lesions generally
occur first, the mean age at symptomatic diagnosis is 24.5 years; for CHBs 33 years is the most common
age for presenting with features (Bahig et al. 2008; Bender et al. 2001).
Molecular genetic analyses enable an early diagnosis of VHL disease in patients who do not satisfy
conventional clinical diagnostic criteria (Maher 2004). On average, the diagnosis of VHL disease is made
4.5 years after the onset of symptoms (Maddock et al. 1996). However, early detection and followup are
essential  for  adequate  management  of  this  syndrome  and  it  is  of  considerable  importance  for  genetic
counselling as well as for the detection of treatable, usually unsuspected lesions, such as RCC, that may
cause early death. Similarly, early detection makes a difference to the prognosis of both PCC and retinal
CHB which need early treatment to avoid severe complications. In addition, there are obvious
consequences for relatives who will require genetic counselling and screening for occult lesions (Filling-
Katz et al. 1991). Before comprehensive screening surveys became routine, the median survival of
patients with the VHL disease was less than 50 years with the main cause of death being complications
linked to RCC and CNS hemangioblastomas (Maddock et al. 1996; Richard et al. 1998)
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Table 1. Key criteria for molecular genetic tests.
1 A patient with classic VHL disease (meeting clinical diagnostic criteria) and/or first-degree
family members
2 An individual from a family in which a germ-line VHL gene mutation has been identified
(presymptomatic test)
3 A VHL-suspected patient, i.e.: a multicentric tumours in one organ b. bilateral tumours c.
two organ systems affected d. one VHL-associated tumour at a young age (i.e. <50 years
for CHB and PCC and <30 years for RCC)
4 A patient from a family with CHB, RCC or PCC only
Capillary hemangioblastoma of the central nervous system
General features
Capillary hemangioblastomas are highly vascular benign tumours of the central nervous system. They are
rare,  accounting for only 1 -  2.5% of all  intracranial  neoplasms (Böhling et al.  2000; Oberstrass et  al.
1996; Surawicz et al. 1999; Zbar et al. 1999). CHBs occur either as a sporadic entity or as part of VHL
disease;  they  are  the  most  common manifestations  of  VHL  disease,  affecting  60  -  80% of  all  patients
(Bahig et al. 2008; Conway et al. 2001; Maddock et al. 1996; Neumann and Bender 1998). They can
arise anywhere along the craniospinal axis, but the cerebellum is the most frequent site, about 44 -72%
of the tumours are localised in the cerebellum, followed by 13 - 50% in the spinal cord, and 10 -25% in
the brain stem. With respect to the spinal tumours, the majority are localised in the thoracic part,
followed by cervical, and to the lesser extent in the lumbar area (Böhling et al. 2000; Choyke et al. 1995;
Filling-Katz et al. 1991; Maher 2004).
CHBs may be the single and only manifestation of the VHL disease, but the tumours are often
multiple in patients with VHL, involving both posterior fossa and the spinal cord (Couch et al. 2000;
Wanebo et al. 2003). CNS tumours in VHL may arise at virtually any age from 11 to 71 years, but the
average  age  of  presentation  for  CHB  is  33  years  (Boughey  et  al.  1990). Approximately  30%  of  all
patients with CHB have the VHL disease and the mean age of  33 years at  diagnosis of  those with VHL
disease is considerably younger as compared with sporadic cases (48 years) (Bahig et al. 2008; Maher et
al. 1990b; Neumann et al. 1989; Richard et al. 1994b).
Regardless of location, CHBs have the same histological characteristics, which relate to Lindau`s
original concept that the disease is an "angiomatosis of the central nervous system" (Choyke et al. 1995;
Lindau 1927). Macroscopically, CHBs appear as well-defined and highly vascular tumours, often cystic but
they contain a solid nodule. Histologically they are composed of two major components, i.e stromal and
endothelial, and furthermore CHBs contain pericytes and scattered mast cells (Böhling et al. 1987;
Choyke et al. 1995). The stromal cells are believed to be the true neoplastic cells of CHB (Vortmeyer et
al. 1997). There are several reports which have associated CHBs with secondary polycythaemia in about
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20% of cases; moreover it has been shown that CHBs harbour cells with erythropoietin-like
immunoreactivity (Bahig et al. 2008; Böhling et al. 1987; Horton et al. 1991; Munt et al. 1992).
Clinical course, diagnosis and treatment
Clinical course.  Although considered histologically as benign, CHBs may cause significant neurological
deficits and are associated with a serious mortality rate. The symptoms associated with CHBs depend on
tumour location, number and size, and are caused by "mass effect", either by the tumour itself or an
accompanying cyst or oedema (Bahig et al. 2008; Gläsker et al. 1999; Maddock et al. 1996). Patients
with CHBs of the brain usually present with a longer history of minor neurological symptoms which in
many cases, are followed by sudden exacerbation necessitating immediate neurosurgical intervention
(Neumann et al. 1989). These tumours may be life-threatening because of large cystic components in the
posterior fossa or they may cause paraplegia if they are localised in the spinal cord.
Symptomatic tumours grow faster than asymptomatic tumours, whereas symptomatic cysts grew
faster than the CHBs associated with them (Filling-Katz et al. 1991; Gläsker 2005).  It has been claimed
that CHBs display several periods of tumour growth separated by periods of arrested growth, though
many  untreated  tumours  may  remain  the  same  size  for  years  (Wanebo  et  al.  2003).  Tumours  in  the
cerebellar hemispheres evoke manifestations due to increased intracranial pressure, and thus headache is
the most frequent presenting symptom. Other typical signs of cerebellar dysfunction are gait ataxia,
dysmetria and nystagmus. The classical polycythaemia, secondary to cerebellar CHB, occurs in about
20% of cases. In severe cases, the tumour can lead to occlusive hydrocephalus with headache, nausea,
vomiting and eventually coma and death. Tumours located in the spinal cord may evoke pain which is
local and can be pinpointed by the patient, sensory loss, spinal ataxia, incontinence and paresis. Spinal
CHBs are more frequently related to VHL than CHBs with an infratentoral localization, (Boughey et al.
1990; Choyke et al. 1995; Gläsker 2005; Maher and Kaelin 1997; Richard et al. 1998). Many individuals
with symptomatic tumours also exhibit asymptomatic lesions. Brainstem tumours may manifest through
symptoms such as orthostatic hypotension and they have a slightly higher likelihood of being
symptomatic than cerebellar or spinal tumours, perhaps due to the constraints of the craniocervical
junction (Filling-Katz et al. 1991). When comparing patients with familial VHL to patients with sporadic
tumours, familial cases have multifocal lesions more often than their sporadic counterparts. However, no
significant differences between sporadic and hereditary CHBs are noted in the radiological features, or in
the duration of symptoms (Neumann et al. 1989; Neumann et al. 1992).
Diagnosis. The method of choice for early diagnosis and follow up examination of CHB is MRI
(Figure 1.). MRI scanning has the advantages of being more sensitive and posing less radiation risk as
compared to computer tomography (Maddock et al. 1996; Resche et al. 1993). Usually the diagnosis can
be established by MRI because of the typical appearance of the tumour, MRI displaying a typically bright
enhancing mass, clearly delineated from the surrounding brain or spinal cord tissue (Bahig et al. 2008;
Baker et al. 2000). Although the detection of an asymptomatic CHB of the CNS does not necessarly mean
intervention  is  inevitable,  early  detection  can  facilitate  patient  management  and  thus  VHL  disease
patients  and  at-risk  relatives  may  be  offered  MRI  scans  every  24  -  36  months  (Maher  2004).
Angiography reveals a highly vascular tumour blush and it can be performed preoperatively to
demonstrate the feeding vessels (Malis 2002; Spetzger et al. 1996; Van Velthoven et al. 2003).  In rare
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cases,  where the diagnosis of  CHBs is  not clearly visualized by MRI and a history of  VHL, angiography
may remain a useful diagnostic tool (Malis 2002; Richard et al. 1998; Van Velthoven et al. 2003).
Since 50% of all CNS CHBs require emergency neurosurgical treatment, early identification of this
tumour would avoid such situations. All VHL patients and their at-risk relatives (unless excluded by
molecular testing) should be offered regular surveillance starting from childhood; ophthalmic examination
should be initiated within the first 2 years of life and MRI after 10 years of age (Filling-Katz et al. 1991).
Improved  surveillance,  earlier  diagnosis  of  lesions  by  modern  imaging  and  laboratory  studies,
improvements in treatment,  and increased knowledge of  this  disease have improved the prognosis and
reduced the complications related to these tumours (Lamiell et al. 1989; Maher et al. 1990b; Neumann et
al. 1992).
Treatment. The  primary  treatment  is  the  surgical  removal  of  the  tumours.  Total  neurosurgical
excision with the use of a high power microscope remains the curative treatment of symptomatic CHBs
and often has to be done as emergency treatment (Neumann et al. 1992). In VHL patients, CHBs often
grow at several sites simultaneously and new lesions can arise with time. Furthermore, the growth
pattern can be irregular and unpredictable; therefore the indication for surgery in asymptomatic cases is
still a matter of debate. However, there is a general consensus for surgical treatment of symptomatic
CHBs (Lonser et al. 2003c). There have been some suggestions that asymptomatic tumours showing
radiographic progression should be operated, since preoperative symptoms are usually not reversible
whereas surgery is associated with low morbidity (Gläsker 2005).
Due to the potential morbidity associated with resection of multiple craniospinal CHBs, for small or
medium sized CHBs (< 30mm), external-beam radio therapy and gamma knife radio-surgery can be used
to arrest the progression of symptoms, by forcing the tumours to shrink or stop growing (Chakraborti et
al.  1997;  Chandler  and  Friedman 1994;  Niemelä  et  al.  1996).  Although  microsurgery  has  considerably
improved post-operative results, multifocal tumour development and recurrence remain a serious
problem in the clinical management of VHL patients.  Due to their susceptibility to tumour growth,
patients  suffering  from  VHL  are  recommended  to  undergo  follow-up  MRI  investigation  at  one  year
intervals, and those without CNS manifestation at two years intervals (Russell and Theis 2003).
A. B. C.
Figure 1. MRI detection of capillary hemangioblastoma tumours. A. Cerebellum. B. Brain stem. C. Spine (arrow).
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Pheochromocytoma
Introduction and genetic characteristics
Pheochromocytoma is a rare neuroendocrine tumour of the chromaffin cells that contain catecholamine-
containing neurosecretory granules. PCC mostly arises in the adrenal medulla but also in ganglia of the
sympathetic nervous system. The term extra-adrenal (paraganglioma) has been widely used to describe
tumours of the paraganglion system localized extra-adrenally, in the retro-peritoneum, pelvis, thorax,
and adjacent to major vessels of parenchymal organs. These two types often share the same clinical
course and are histologically equivalent (Koch et al. 2001; Neumann et al. 2002b).
Multiple genetic alterations have been associated with PCC. Most PCCs are sporadic, but they can
also occur in inherited tumour syndromes.  A familial predisposition is seen in patients with VHL disease
(Pacak et al. 2001), multiple endocrine neoplasia type II (MEN II) and neurofibromatosis type 1 (NF1),
(Brandi et al. 2001; Eng et al. 1996; Walther et al. 1999). Germ-line mutations in three of the succinate
dehydrogenase subunit genes (SDHD, SDHB and SDHC) have been shown to be responsible for the
familial occurrence of adrenal and extra-adrenal (paraganglioma) PCCs (Maher  and  Eng  2002).  It  has
been estimated that approximately 10% of PCCs are familial cases; however, recent studies indicate that
the percentage could be as high as 24% (Neumann et al. 2002).
Pheochromocytoma in von Hippel-Lindau disease
Pheochromocytoma occurs in 10 to 34% of VHL patients, and it is the presenting manifestation in about
5% of the cases. The mean age at diagnosis is 28 years and in about 50% of the cases,  the tumours are
bilateral (Maher et al. 1990b; Richard et al. 1994b; Walther et al. 1999).
VHL disease has been divided into four subtypes based on the central role of PCC. VHL-type 1 is
without  PCC,  and  VHL-type  2  presents  with  PCC.  A  distinct  subtype  of  type  2  patients  (type  2C)  will
develop PCC only, without any other manifestation of VHL disease (Table 3). More than 300 VHL germ-
line mutations have been identified, and those associated with PCCs are nearly all of the missense type
(Brauch et al. 1995a; Chen et al. 1996; Hes et al. 2003; Neumann et al. 2002a; Zbar et al. 1996).
About 15% of patients with VHL-associated PCCs have large germ-line deletions detected by
Southern blot analysis (Richards et al. 1993). A mutation hotspot has been described at codon 167 (nt
712/713) in exon 3 (Chen et al. 1995; Crossey et al. 1994). "Founder effects", such as those present in
the Black Forest region in Southern Germany with the missense mutation occurring at codon 98
(Tyr98His), may explain regional prevalence rates (Neumann 1993; Neumann et al. 1993).
Pheochromocytoma and other inherited tumour syndromes
Multiple endocrine neoplasia 2 is an autosomal dominant tumour syndrome and it is divided into three
subgroups, MEN 2A, MEN 2B and familial medullary thyroid carcinoma (FMTC). PCCs occur only in MEN
2A and MEN 2B, each with a rate of 50%. All patients with MEN 2 have germ-line mutations in the RET
proto-oncogene (10q11.2) (Brandi et al. 2001; Eng et al. 1996). The prevalences of MEN 2 and VHL are
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similar, 1 in 35 000 individuals, but mutations predisposing to PCC have a greater penetrance in MEN 2 in
comparison to VHL. The mean age at diagnosis is about 37 years and in most cases PCCs occur bilaterally
and multifocally (Koch et al. 2002; Maddock et al. 1996; Ponder 1999).
Approximately 1% of the patients diagnosed with PCC have NF1 disease.  NF1 is the most common
familial cancer syndrome predisposing to PCC. The disease is caused by germ-line mutations in the NF1
gene, located on 17q11.2 (Huson et al. 1988; Riccardi 1991). PCC in patients with NF1 occurs at a later
age as compared to occurrences in MEN2 and VHL disease. The mean age at diagnosis is during the fifth
decade, and in fact  onset before the age of  20 years is  uncommon (Knudson and Strong 1972). About
22% of  NF1  patients  with  PCC  have  multiple  or  bilateral  tumours,  less  than  12% of  the  PCCs  in  NF1
patients are metastatic, and extra-adrenal PCCs in patients with NF1 are rare (Gutmann 1997; Howe et
al. 1993; Koch et al. 2001; Walther et al. 1999).
Paraganglioma is a genetically heterogeneous condition; it arises in extra-adrenal chromaffin tissue,
such as the organ of Zuckerkandl. The genetic foundations of this disorder remain largely unknown. The
most common tumour site is the carotid body. In some of these tumours, a germ-line mutation in SDHD
has been identified. The SDHD gene is located on chromosome 11q23, SDHC at 1q21, and SDHB at 1p36
(Astuti et al. 2001; Baysal et al. 2000). Recent studies suggest that germ-line SDHD and SDHB
mutations are an important cause for familial and isolated PCCs (Maher and Eng 2002; Neumann et al.
2002).
Sporadic pheochromocytomas
Hereditary tumours and their sporadic counterparts often share the same genetic background. Although
the etiology of most inherited forms of PCCs is rather well documented, little is known about the etiology
of sporadic tumours. Mutations of those genes that harbour germ-line mutations in familial cases account
for only 10 -15 % of somatic mutations in sporadic PCCs (Bar et al. 1997; Bender et al. 2000; Brauch et
al. 1997; Koch et al. 2002a).  Somatic intragenic VHL mutations are infrequent, seen only in about 8% of
sporadic PCCs. Similarly, somatic RET mutations are also uncommon, only found in about 10 - 20% of
cases (Eng et al. 1995; Hofstra et al. 1996; Januszewicz et al. 2000). Gutmann and co workers described
a somatic mutation of NF1 in 7/20 (35%) sporadic PCCs suggesting that NF1 inactivation may be
involved in the pathogenesis of non-familiar PCCs (Gutmann 1994). Furthermore, mutation analyses of
SDHD and SDHB in  sporadic  PCCs  have  revealed  only  a  single  somatic  mutation  (Astuti  et  al.  2001;
Gimm et al. 2000). Recently (Neumann et al. 2002) identified germ-line mutations in RET, VHL, SDHB ,
SDHC, SDHD in up to 24% of studied patients with apparently sporadic PCCs and they suggested that
among all PCCs, more than 24% may be attributed to one of those six genes. However, allele losses on
chromosome 1p, 3p and 17p, 22q are also common findings in familial and sporadic PCCs (Bender et al.
2000; Benn et al. 2000; Vargas et al. 1997). A recent cytogenetic analysis indicated frequent loss of 6q
in sporadic PCCs (Dannenberg et al. 2000).
Clinical presentation
Pheochromocytomas are rare, in Finland only about 10 - 15 cases are diagnosed annually. PCCs can
occur  at  any  age,  but  the  peak  age  at  diagnosis  is  the  fifth  decade  of  life.  In  general,  genetically
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predisposed patients are younger at diagnosis and have more often multifocal tumours compared to
patients with sporadic PCCs (Lack 1997).
Hypertension is the most common clinical sign in all patients with PCC, this kind of hypertension can
be sustained or paroxysmal and may lead to death from cardiovascular or cerebrovascular disease. It has
been estimated that only about 0.1 - 0.3% of hypertensive patients have an underlying PCC (Bravo
1994). The most typical presentation of a PCC is a paroxysmal hypertensive crisis characterized by
severe hypertension, diaphoresis, headaches and tachycardia or arrhythmia. Hypertensive episodes can
be spontaneous or associated with physical exercise, surgical operation, defecation (Sutton et al. 1981).
The clinical symptoms of PCCs derive from the catecholamines they secrete and from their relative
stimulation of alpha or beta-adrenergic receptors. Catecholamines are normally produced by sympathetic
nerves  and  by  the  adrenal  medulla.  High  catecholamine  levels  are  not  specific  for  PCC,  because
sometimes PCCs do not secrete enough catecholamines to produce signs and symptoms. The secretion
may also be episodic and between episodes, levels of catecholamines may be normal (Bravo 1994;
Eisenhofer et al. 1999; Gerlo and Sevens 1994; Pacak et al. 2001).
Diagnosis of PCC usually requires biochemical evidence of excessive catecholamine production by the
tumour, which usually is achieved from measurements of catecholamines or catecholamine metabolites
(metanephrines, normetanephrines and vanillylmandelic acid) in urine or plasma. Measurements of
plasma levels of normetanephrine and metanephrine have higher sensitivity and specificity than the other
biochemical tests for the diagnosis of both familial and sporadic PCC (Bravo 1994; Gerlo and Sevens
1994). In familial PCC, periodic screening can lead to early stage detection before symptoms and signs,
at a point when tumours are small and are not secreting large amounts of catecholamines (van der Harst
et al. 2002). Plasma concentrations of normetanephrine greater than 2.5 pmol/ml or metanephrine levels
greater than 1.4 pmol/ml (more than 4 and 2.5 fold above the upper reference limits) indicate a PCC with
100% specificity (Bahig  et  al.  2008;  Lenders  et  al.  2002;  Pacak  et  al.  2001).  The  tumour  can  be
anatomically localized using CT, MRI, or metaiodobenzylguanidine (MIBG) scanning (Berglund et al.
2001; Pacak et al. 2001). Positron emission tomography (PET) has been also used to visualize primary
and metastatic tumours (Pacak et al. 2001).
Although most PCCs are benign, about 10% of them may be malignant, and cause metastases. In
MEN  2  and  VHL  related  PCCs,  about  25%  are  reported  as  being  malignant  over  a  25  year  follow-up
penlod. At present, there is no definite histological marker which can differentiate between benign and
malignant  PCCs  (Salmenkivi  et  al.  2001).  It  is  believed  that  a  better  understanding  of  the  molecular
biology of PCCs by identification of the genes involved in the tumourigenesis will help surveillance, early
diagnosis and the development of more effective treatment modalities (Pacak et al. 2001). Studies show
that genetic testing for RET, VHL, NF1, SDHD, SDHB and SDHC gene mutations does represent a useful
means to diagnose those PCCs that have occurred as the first manifestation of these hereditary diseases.
The authorities recommend screening for PCCs to be started at the age of 6, since PCC has been
described in children as young as 10 to 12 years old (Neumann et al. 1993).
The definitive treatment for PCC is surgical resection of the tumour, but surgery has a great risk for
complications  because  of  excessive  release  of  catecholamines  from  the  tumour  which  can  lead  to
hypertensive crisis, stroke, arrhythmias, or myocardial infarction.  Preoperatively patients must thus
undergo pharmacological blockade of catecholamine synthesis and receptors (Kercher et al. 2002;
Okamoto  et  al.  1996;  Pacak  et  al.  2001;  Walther  et  al.  1999;  Walther  et  al.  2000).  Recurrent  PCC
develops in 20% of patients with VHL; in MEN2 the prevalence is as high as 33%.
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The principles of managment of malignant PCC include pharmacological control of symptoms and
tumour mass reduction by surgical resection of the primary tumour and metastases, followed by
radionuclide therapy with or without chemotherapy (Eisenhofer et al. 2004; Hartley et al. 2001). Hepatic
resection should be considerd for local liver metastases; however less invasive techniques such as arterial
embolisation or chemoembolization, cryoablation, and radiofrequency ablation will provide a transient
response (Pacak et al 2001). Treatment with high dose I-MIBG results in an objective tumour response,
stabilization of disease and a reduction in catecholamine secretion. Chemotherapy can be used alone or
in combination with radionuclide therapy, particularly when there is extensive residual disease or poor
uptake and response to radionuclide treatment (Joel et al. 2008).
Other VHL- associated tumours and lesions
Retinal hemangioblastoma
Retinal capillary hemangioblastomas are the most frequent and earliest detected lesions associated with
VHL  disease  and  they  are  histologically  identical  to  the  CHBs  of  the  CNS  (Grossniklaus  et  al.  1992;
Webster et al. 1999). The lesions are usually peripheral in the retina or near the optic disc or both.  A
dilated feeding artery and vein is typically present, and microaneurysms can be seen (Dollfus et al.
2002). They are frequently multiple and bilateral, about 60% of VHL patients exhibit retinal CHB. The
mean age at diagnosis is 25 years, retinal CHBs have been diagnosed in 1 - 2 year old infants, but this is
rare, only 5% of the cases are diagnosed in children younger than 10 years of age (Bahig et al. 2008;
Maher et al. 1990b; Moskowitz et al. 2005; Niemelä et al. 2000).
They are usually asymptomatic if they are in peripheral location, but if they become large or if they
are located centrally, they can cause profound vision loss. Both peripheral and central angiomas can
cause exudative and tractional retinal detachment, and hemorrhage as they enlarge, leading to blindness
(Russell and Theis 2003; Wittebol-Post et al. 1998). Ophthalmoscopy allows identification of most retinal
tumours. Routine use of fluorescein angiography can be used for detecting peripheral and optic nerve
lesions. It is recommended that screening examination with dilated fundoscopy should be done in a VHL
patient at least once a year, starting at age 1 year (Neumann and Wiestler 1991).
Early  diagnosis  and  treatment  can  prevent  visual  loss  or  blindness.  The  treatment  consists  of
aggressive use of laser photocoagulation or cryotherapy since most peripheral retinal tumours do respond
to treatment. Irreversible glaucoma associated with severe pain can be an indication for enucleation
(Martz 1991; Singh et al. 2001). The visual prognosis is frequently poor in patients with VHL disease,
about 25% will experience permanent visual loss (Moskowitz et al. 2005).
Renal cell carcinoma
Renal cell carcinoma occurs predominantly as a sporadic disease, but to a lesser extent also as part of
the VHL disease. RCC rarely is found as a first manifestation of VHL disease, since eye and CNS findings
usually precede the discovery of renal involvement. However, RCC has been reported to develop in up to
45%  of  patients  with  VHL  disease  (Gnarra  et  al.  1993;  Maher  et  al.  1990b).  VHL-associated  RCC  is
frequently  multicentric  and  occurs  at  a  younger  age  than  in  the  sporadic  forms:  the  mean  age  at
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diagnosis  is  39  years,  20  years  younger  than  is  the  case  for  the  sporadic  RCCs  (Bahig  et  al.  2008;
Richard et al. 1994b; Richard et al. 1998). About 50 -70% of patients eventually develop renal cysts, but
these rarely produce significant renal impairment (Richards et al. 1998; Richards FM 1998). The lifetime
risk of  clear cell  RCC is  >70%, and the incidence of  metastasis of  RCC in VHL patients reported to be
20%, usually at the sites in the liver, lung and bones. RCC is the most common cause of death in VHL
disease (Maher et al. 1990b; Neumann 1987).
Usually RCCs are asymptomatic, but occasionally the more advanced cases of RCC can present with
haematuria,  and  flank  pain;  thus  serial  imaging  of  the  kidneys  is  useful  for  early  diagnosis  in  VHL
patients. Due to the absence of early clinical symptoms and the importance of early detection, diagnosis
during presymptomatic screening has the potential to enhance overall outcome. Renal US and contrast-
enhanced MRI are useful in helping to determine whether a lesion is cystic or solid. CT allows detection
and quantification by size and number of RCC and cysts (DrRussell R Lonser MD and K Libutti MD 2003;
Lonser et al. 2003a). Angiography is not as sensitive as the other techniques for the detection of RCC,
and it is used only for preoperative screening to identify the renal vascular supply prior to partial
nephrectomy (Goldfarb 1998).
Previously the presence of bilateral renal tumours has been taken as an indication for bilateral
nephrectomy and kidney transplantation. However, recently nephron-sparing surgery has been
recommended  for  carcinomas  that  have  a  maximum  diameter  of  3  cm.  Renal  sparing  resection  is
designed to reduce the risk of metastasis while still preserving kidney function. For patients and at-risk
relatives under regular surveillance, renal tumours should be detected at an early symptomatic stage and
followed until they are approximately 3 cm in size (Walther et al. 1995; Walther et al. 1999).
Cysts and other tumour types
Endolymphatic sac tumours are slow growing, low grade papillary adenocarcinomas, rare in the general
population but associated with VHL disease in up to 10% of patients, and they are frequently bilateral.
Though they are mostly asymptomatic, they may evoke partial or even hearing loss, tinnitus, a sense of
disequilibrium and facial paresis (Manski et al. 1997). They are highly vascular, and often erode or
expand the surrounding temporal bone. Histologically they differ from CHBs but are similar to the
papillary cystadenoma of the epididymis. They are not known to metastasize but are locally aggressive.
CT and MRI of the internal auditory canals are the recommended radiological examination techniques for
diagnosis  of  endolymphatic  sac  tumours  (Blamires  et  al.  1992).   Surgery  is  curative  for  completely
excised tumours, and the preoperative level of hearing is usually preserved (Lonser et al. 2003b).
Epididymial cystadenomas are benign, seen in approximately 25 - 60% of men with VHL disease.
They can be multiple and bilateral, firm and easily palpable, typically appearing in the teenage years
(Wernert et al. 1986). They are characteristically asymptomatic, but sometimes the patient may report a
hard,  smooth  "pebble"  in  the  scrotum.  Infertility  due  to  azospermia  has  been  reported  (Lamiell  et  al.
1989). The diagnosis is made by palpation and confirmed by MRI and US. Since the lesion is benign and
typically asymptomatic, they are managed conservatively.
Broad ligament cystadenomas, papillary cystadenomas in the broad ligament have occasionally
been reported but these may go unrecognised in many women with VHL. The mean age at presentation
and the true frequency are unknown. The earliest age at which this tumour has been diagnosed is 16
years, but it was reported that the usual age of onset is between 22 and 46 years. It can be diagnosed by
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CT-imaging or US, MRI. The tumours are grossly and histologically similar to epididymal cystadenomas.
Since they are benign and typically asymptomatic, they can be managed conservatively (Funk and Heiken
1989; Lonser et al. 2003b).
Pancreatic cysts,  there  is  frequent  involvement  of  these  cysts  in  VHL  disease,  in  most  cases
multiple cysts occur, which are rarely of functional significance, and they vary in size from several
millimetres to over 10cm. (Choyke et al. 1995; Libutti et al. 1998; Libutti et al. 2000; Maher and Kaelin
1997). They are benign, generally asymptomatic, and become evident only when they cause bile duct
obstruction. Periodic imaging of asymptomatic individuals is important for diagnosis. Most commonly
detected with CT and US; once this cyst is identified with CT, MRI can be used to confirm the diagnosis. If
they  are  asymptomatic  then  followup  is  recomended;  however,  if  they  are  symptomatic,  the  specific
approach to treatment, is determined by location and size of the cyst > 3cm.
Genetic mechanisms of the VHL disease and capillary
hemagioblastoma
Adaptation to decreased oxygen tension is a fundamental requirement of all living organisms. At the
molecular level, this adaptation to hypoxia involves induction of hypoxia responsive genes such as
erythropoietin (Epo) and vascular endothelial growth factor (VEGF), the former to increase blood oxygen
carrying capacity and the latter to increase blood delivery. New blood vessel formation or angiogenesis is
also an adaptive response to cell and tissue hypoxia (Kaelin 2005; Shweiki et al. 1992). Tumour
angiogenesis that is required for tumour growth is recognised as a response to hypoxia. Solid tumour
growth is dependent upon the angiogenesis in the tumour induced by angiogenic factors such as VEGF.
Vascularisation provides the tumour with nutrients and oxygen as well as the ability to establish
metastasis via the circulatory system (Levy et al. 1997; White et al. 1995).  VEGF, also known as
vascular permeability factor, is a potent angiogenic factor, which is regulated by hypoxia in vitro and in
vivo (Leung et al. 1989). Many tumour cell lines have been demonstrated to constitutively overexpress
VEGF (Levy et al. 1997).
VHL gene and protein
The human VHL gene located at 3P25-26 and contains 856bp in three exons. It encodes a protein that
contains 213 amino acids with no significant homology to any other known proteins (Figure 2) (Duan et
al. 1995). Depending on the site of the translation initiation codon, it encodes two proteins of different
size (pVHL19 and pVHL30). Both isoforms appear to retain tumour suppressor activity, and the term
"pVHL" is used to refer to both isoforms generically since their function is similar (Duan et al. 1995; Kim
and Kaelin 2004).
Tumours linked to VHL inactivation are often highly vascular and overproduce angiogenic factors
such as VEGF (Böhling et al. 1996). VEGF and Epo are normally induced under conditions wher there is
inadequate oxygenation. However, cells lacking pVHL constitutively over-produce hypoxia-inducible
mRNAs and the restoration of pVHL function results in down-regulation of hypoxia-inducible mRNAs in the
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presence of oxygen. Thus overproduction of hypoxia-inducible gene expression is a hallmark of pVHL-
defective cells (Iliopoulos et al. 1996; Kim and Kaelin 2004).
Several studies have revealed that a cellular transcription factor, Elongin (SIII), is a functional target
of  the  pVHL. Elongin (SIII) comprises a transcriptional active subunit (A) and two regulatory subunits
Elongin (B and C). pVHL can compete with elongin A for binding to elongins B and C, thereby inhibiting
elongin/SIII activity (Duan et al. 1995; Kibel et al. 1995). pVHL, when bound to elongin B and elongin C,
interacts  with  a  fourth  protein  called  Cul2,  (Aso  et  al.  1995;  Kibel  et  al.  1995;  Kishida  et  al.  1995;
Zimmer et al.  2004).  These pVHL/elongin/Cul2 (VCB) complexes interact with a protein called Rbx1, a
complex target protein destined for polyubiquitination (these enzymes are often referred to as ubiquitin
ligases) and hence the presence of the polyubiquitin tail serves as a signal or flag for the substrate to be
degraded (Maina et al. 2005; Maynard and Ohh 2005). In another words, the VCB complex targets
substrates for intracellular degradation via a process called ubiquitination. In this process, the target is
bound by a protein called ubiquitin that labels a protein for degradation The destruction takes place inside
the proteasome, a protein-digesting complex (Ohh et al. 1998).
The VHL gene product, pVHL, has multiple functions, but the one most extensively studied relates to
the regulation of the transcription factor called hypoxia-inducible factor (HIF). Many of the genes that are
regulated by hypoxia including VEGF and EPO are under the control of hypoxia-inducible factor. HIF is
made up of two non-identical subunits, the ? and ? subunits, and it binds to specific DNA sequences
(Kaelin 2007b; Kim and Kaelin 2004). The  HIF  ? is  a  stable  protein,  whereas  HIF  ? protein  is  highly
unstable  if  oxygen  is  present,  thus  the  formation  of  an  active  HIF  heterodimer  is  restricted  to  hypoxic
conditions. Recently it was reported that cells lacking pVHL fail to degrade HIF ? subunits in the presence
of oxygen, thus providing an explanation for the expression of HIF target genes in pVHL-defective cells
(Cockman et al. 2000; Iliopoulos et al. 1996; Kaelin 2007b; Kim and Kaelin 2004; Maxwell et al. 1999).
The VEGF gene is one of the possible target genes regulated by HIF (Maxwell et al. 1999). Moreover
it was shown that the region of pVHL that binds to elongins B and C is frequently mutated in VHL disease,
evidence that tumour suppression by VHL is linked to its ability to inhibit elongin /SIII in vivo (Duan et al.
1995; Kibel et al. 1995; Maxwell 2005). When hypoxia-inducible proteins are not properly degraded, an
excessive blood vessel formation may occur. Thus in cells lacking wild-type pVHL, degradation of HIF is
impaired and cells behave as if they were deprived of oxygen (Michelle et al 2008).
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Figure 2. Function of wild-type and mutant pVHL in a simplified model which illustrates targeting of HIF-? for
degradation by the pVHL E3 ubiquitin ligase complex (modified from Michelle et al 2008)
(A) In normoxia, key proline residues of HIF-? are hydroxylated by PHDs (prolyl hydroxylase domain-containing
proteins).The functioning of PHDs is dependent on the presence of molecular oxygen. This hydroxylation process
enables recognition of HIF-? by  the  pVHL/E3  ubiquitin  ligase  complex.  HIF-? is polyubiquitinated and subsequently
degraded by the 26S proteasome. (B) In normoxia, VHL gene mutations in the ? or ? domain can disrupt the binding
of pVHL to HIF-? and/or to the other components of the E3 ubiquitin ligase complex. Stabilized HIF-? dimerizes with
HIF-1?. Co-activators are recruited and the HIF complex can activate the transcription of target genes undernormoxic
conditions. Ub, ubiquitin.
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Germ-line mutations
Inactivation of the VHL gene is believed to be responsible for the development of both sporadic and
familial cases of CHB (Figure 3, table 2) (Choyke et al. 1997; Fearon 1997; Goldsmith and Thomas 1999;
Maher et al. 1991). Most individuals with the disorder inherit a germ-line mutation of the gene from an
affected parent and a normal (wild type) gene from the unaffected parent (Latif et al. 1993; Maher et al.
1990b; Neumann and Wiestler 1991). A germ-line mutation of the VHL gene is present in all the cells of
the affected individuals who inherit the genetic trait. However, only those cells that undergo a deletion or
mutation of the remaining wild type allele in susceptible target organs develop tumours (Russell and
Theis 2003). The first hit (germ-line mutation) is typically a localised intragenic mutation (e.g., point
mutation, microdeletion, etc.) and the second hit is a somatic DNA alteration which is acquired during the
patient's lifetime and is present only in tumour tissue. Such secondary events are frequently large
deletions or mitotic recombination events resulting in LOH. (Gläsker et al. 2001; Kaelin 2004). So far
germ-line mutations of the VHL gene have been reported in >500 VHL kindreds and the success for
detecting a Germ-line mutation in cases expected to carry one has been 100% (Corless et al. 1997;
Crossey et al. 1993; Maher 2004; Tse et al. 1997; Zbar et al. 1996; Zbar et al. 1999). The improvement
in detection of germ-line VHL mutations is related to the use of quantitative Southern blotting and
fluorescence in situ hybridization. Though also direct sequencing, LOH and hypermethylation studies have
been conducted (Herman et al. 1994; Stolle et al. 1998). Currently close to 800 different VHL germ-line
mutations of different types are known (Beroud et al. 2000).
VHL mutations are extremely heterogeneous in both their type and position, and are distributed
widely  throughout  the  coding  sequence,  sparing  the  first  54  and  the  last  13  codons.  Germ-line  VHL
mutations may be divided into three groups (Table 3), (i) large deletions (including deletions
encompassing  the  entire  gene),  detectable  in  about  25  -  40%  of  patients,  (ii)  intragenic  missense
mutations in about 30% of the patients, and (iii) microdeletions (1 - 18 bp) and other protein truncating
mutations (nonsense, frame shift insertions of 1 -8 bp, splice site mutations) detected in approximately
30% of cases (Frederik et al. 2003; Maher 2004; Richard et al. 1994; Friedrich et al. 2001).
By studying different families from different continents and countries (North America, Europe and
Japan) it  was possible to detect a common germ-line mutation and to compare the effects of  identical
germ-line mutations in different populations. Codon 167 mutations were present in VHL families of all
nationalities tested. These mutations produced similar phenotypes in Caucasian and Japanese families
(Zbar et al. 1996).  Missense mutations at nucleotide 712 (codon 238) represent a mutational hot spot
found in different unrelated families and mutations at this site are associated with a high risk of PCC
(Chen et al. 1995). Another "hot-spot" site identified in the German study is a mutation at nucleotide
505T>C (the Black Forest - founder mutation), that is associated with a high risk for PCC but without RCC
(Brauch et al. 1995a). However not all missense mutations predispose to PCCs; according to a Japanese
study, mutations found in 22 VHL patients without PCC consisted of 11 missense mutations (Clinical
Research Group for VHL in Japan, 1995).
Although most index cases with VHL disease have a positive family history of VHL, some do not and
may represent de novo cases. Cases without a family history of VHL may or may not have a germ-line
mutation in the VHL tumour-suppressor gene. Patients diagnosed without a family history of the disease
have been reported in as many as 23% of the kindreds with VHL.
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First-generation diagnoses may result from a new mutation occurring during oogenesis or
spermatogenesis in the parent. Another possibility is that the seemingly unaffected parent is mosaic for
the disease.  Mosaicism is defined as the presence in an individual of at least two cell lines differing in
genotype  and  arising  from  a  single  zygote  (Austin  and  Hall  1992).  Depending  on  the  stage  of
development and the cell in which the mutation occurred, the individual may be unaffected or may suffer
a clinical disease (Zlotogora 1998). The finding of mosaicism has important implications both in
counselling family members and in risk assessment for disease development in the individual with VHL
mosaicism (Sgambati et al. 2000; Zlotogora 1998).
Figure 3. Functional domains of the VHL protein and distribution of germ-line mutations (from VHL database).
Hotspots for mutations are readily visible at amino acids 67–117 HIF binding domain and 157–170 [Elongin C (EloC)
binding domain]. (Modified from Richard 2002).
Somatic mutations
In sporadic tumours, tumourigenesis is thought to be initiated by a somatic alteration of both alleles of a
TSG responsible for the corresponding hereditary tumour syndromes. As opposed to the situation in the
heritable disease where the first hit occurs in the germ-line, in sporadic tumours, both the first and
second hit occur somatically (i.e, after conception) (Gläsker et al. 2001; Kaelin 2004). Combining all the
investigated data together, it has been possible to exhibit a mutation of the VHL gene in only 20% - 50%
of sporadic tumours (Gläsker et al. 2001; Zbar et al. 1999). The intragenic  distribution of somatic VHL
mutations is similar to that of germ-line mutations,  except that somatic mutations are relatively more
frequent in exon 2 (Foster et al. 1994; Gnarra et al. 1994).
Somatic mutations of the VHL gene  have  been  documented  in  sporadic  CHBs  in  up  to  30% cases
(Brauch et al. 1995a; Kanno et al. 1994; Olschwang et al. 1998). LOH at the VHL gene locus has been
detected  in  52%  of  the  stromal  cell  component  of  sporadic  CHBs  (Lee  JY  1998),  However,
hypermethylation of VHL in sporadic CHB has not been detected to date (Kaelin 2004). Somatic VHL
mutations and allele loss can be detected in up to 60% of clear cell RCC, and in most cases there is loss
of the remaining VHL allele (Decker et al. 1997; Kondo and Kaelin 2001). Furthermore transcriptional
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silencing by promoter hypermethylation occurs in RCC cell lines in 10% to 20% of sporadic primary clear
cell RCC (Herman et al. 1994; Prowse et al. 1997). No differences were exhibited in the mutation
frequency comparing early and advanced stages of RCC (Maher and Kaelin 1997). However somatic VHL
mutations are uncommon in sporadic PCCs, less than 8% of cases display a VHL mutation (Eng  et  al.
1995; Kanno et al. 1994; Koch et al. 2002b). The mutations that have been detected are missense
mutations, suggesting that specific mutations are required to instigate PCC, analogous to the missense
mutations predominantly associated with the development of PCC VHL in type 2 disease.
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Table 2. Summary of genetic alterations of VHL-associated tumours, with gene inactivation by epigenetic
mechanism also indicated.
Author No of samples
Familial/
Sporadic
Mutations %
Germ-line /
Somatic
Methods used LOH % Methylation
Crossey et al. 1994 94/ - 59/ - SSCP/ Heteroduplex - -
Herman et al. 1994 - /26 - /19 Methyl + +
Kanno et al. 1994 - / 13 - / 20 SSCP/ Direct sequencing - -
Brauch et al. 1995 - /62 - /3 SSCP - -
Chen et al. 1995 114/ - 75/ - SSCP/ Dideoxy
sequencing
- -
Clinical Research Group for
VHL in Japan 1995
45/ - 57/ - SSCP/ Southern blotting - -
Oberstrass et al. 1996 - /20 10/40 SSCP/
Heteroduplex/Direct
sequencing
- -
Zbar et al. 1996 469/ - 63/ - SSCP/ DGGE/ Dideoxy
sequencing
- -
Prowse et al. 1997 - /15 - /46 SSCP/ Direct sequencing + +
Tse et al 1997 3/5 100/40 SSCP/ Direct sequencing 66/40 NI
Lee et al. 1998 - /20 - /52 SSCP/ Direct sequencing + +
Olschwang et al. 1998 92/18 67/11 DGGE/ Direct
sequencing/ Southern
blotting
- -
Stolle et al. 1998 93/ - 100/ - Quantitative Southern
blotting/ FISH/ Direct
sequencing
- -
Webster et al. 1999 183/ - 88/ - SSCP/ Southern blotting/
Direct sequencing
- -
Niemelä et al. 2000 8/21 75/ - Direct sequencing - -
Yoshida et al. 2000 - /240 - /50 SSCP/ Direct
sequencing/ Southern
blotting/ Methyl/ LOH
+ +
Gläsker  et al. 2001 29/13 94/23 SSCP/ LOH/ Southern
blotting
62/50
Gijtenbeek et al. 2002 7/16 86/31 Direct sequencing
SSCP= single strand confirmation polymorphism; DGGE= denaturing gradient gel electrophoresis; FISH= fluorescent in situ
hybridization; LOH= loss of heterozygosity; Methyl= Gene promoter methylation analysis; -= not included or studied; +=
detected; NI= no information.
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Genotype - phenotype relations
As many as 50% of patients in VHL families may exhibit only one manifestation of the syndrome (Maher
et al. 1991; Neumann and Wiestler 1991). Some individuals in the same family may present with a life-
threatening disease with multiple tumours and suffer a considerable reduction of lifespan, whereas other
patients have only few manifestations of  the disease with no impairment of  life (Catapano et al.  2005;
Lamiell et al. 1989). Several studies have been performed to determine the nature and distribution of the
mutations responsible for VHL disease, furthermore to correlate the mutations with neoplastic
manifestations, and clear genotype-phenotype correlations have emerged.
Interfamilial differences in the presence of PCC are well recognised in VHL disease. The frequency of
different mutation classes has been compared between kindreds with and without PCCs, and the type of
VHL mutation appears to correlate with the clinical manifestations of the disease. Missense mutations are
more frequent among families affected by PCC than in those families in whom PCC has not appeared
(Friedrich 2001).
Thus, studies have classified VHL families into two types based on the presence or absence of PCC,
VHL type 1 without PCC, and VHL type 2 with PCC (Table 3). The types of mutations responsible for VHL
type 1 differed from those responsible for VHL type 2. Micro-deletions / insertions, nonsense mutations or
deletions, splice site mutations and mutations that lead to a complete loss of the VHL gene product are
associated with VHL type 1. In contrast, most of the mutations identified for VHL type 2 were missense
point mutations.
Mutations found in codon 238 account for most of the mutations identified for VHL type 2, and are
strongly predictive of a predisposition to develop PCC (Chen et al. 1996; Linehan et al. 1995; Neumann
and Wiestler  1991; Neumann and Bender 1998; Zbar 1995).  However,  not all  missense mutations are
associated with a high risk for PCCs only. Some PCC-associated missense mutations are also associated
with a high risk for RCC. The intragenic nucleotide (nt)c. 712 C>T mutation is associated with a high risk
of both PCC and RCC (Green et al. 1986). On the contrary, the nt 505 T>C mutation is associated with a
high frequency of PCCs but not RCCs (Brauch et al. 1995a; Glenn et al. 1991). Brauch and co-workers
also described a missense mutation at nt 505 as a founder effect in VHL families of the Black Forest
region where there is a predominance of PCC (Brauch et al. 1995a; Brauch et al. 1995b).
VHL type 2 is  further subdivided into type 2A, where patients develop PCC without RCC, and type
2B, where patients develop both PCC and RCC. Furthermore, it has been noted that some families with
VHL disease have an increased risk of PCC without the other classical signs of VHL disease and this type
is called 2C (Chen et al. 1996; Crossey et al. 1995; Neumann and Bender 1998; van der Harst et al.
2002) (Table 3). Recently it has been demonstrated that there is a higher prevalence of RCC in patients
with partial germ-line VHL deletions relative to complete deletions (Maranchie et  al.  2004).  Gallou and
co-workers proposed that mutations leading to truncated protein (MLTP) are more likely to promote renal
tumourigenesis, and confirmed a key role for MLTP and large rearrangements in conferring genetic
susceptibility to renal lesions in VHL patients (Gallou et al. 2004). Yoshida et al. also found MLTP to be a
risk factor for developing RCC in a Japanese-Asian VHL population (Yoshida et al. 2000).
The detection of a mutation in a proband allows the identification of mutation carriers among family
members who do not yet exhibit any clinical manifestation of VHL. The prognosis for the lifetime risk of
PCC can be estimated by determination of the underlying mutation even if there is no family history of
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VHL. Relatives may benefit from pre-symptomatic detection of elevated tumour susceptibility, followed by
regular surveillance for tumour development. Relatives who do not inherit the mutation will be spared
anxiety  and  the  need  for  regular  monitoring.  The  standard  care  is  for  patients  or  family  members  to
receive genetic counselling before and after undergoing molecular testing.
Table 3. Characteristics of different types of VHL disease and types of mutations related to them
(Brauch et al. 1995a; Chen et al. 1996; Hes et al. 2003; Neumann et al. 2002a; Zbar et al. 1996).
Type of VHL disease Mutation type Clinical Manifestation1
Type 1 Microdeletion (1 -18bp), insertion (1-8 bp)
Large deletion (entire gene), splice site and
nonsense mutation
CHB, RCC but not PCC
Type 2A Missense mutation
(Amino acid substitution)
CHB, PCC but not RCC
Type 2B Missense mutation
(Amino acid substitution)
CHB, PCC and RCC
Type 2C Missense mutation
(Amino acid substitution )
PCC only
1 CHB, Capillary hemangioblastoma; RCC, Renal cell carcinoma; PCC, Pheochromocytoma.
Other candidate tumour suppressor genes
In tumour suppression, genetic and epigenetic mechanisms may act in parallel; bi-allelic inactivation may
occur via a combination of mutational and epigenetic events. With respect to the epigenetic mechanisms,
promoter hypermethylation has been widely recognized as an alternative to genetic alterations as a way
of disrupting gene function (Jones and Laird 1999; Jones and Baylin. 2002).
Previous studies have revealed loss or inactivation of the VHL gene in approximately 20% to 50% of
sporadic CHBs ( Kanno et al 1994; Lee et al 1998; Tse et al. 1997). A CGH-study showed DNA losses on
6q, in addition to those on 3p in sporadic CHBs (Sprenger et al 2001). Moreover in other VHL-associated
tumours particularly in RCCs losses of 6q have been reported (Gronwald et al 1997, Bissing et al. 1999).
These findings imply that chromosome 6q may harbour genes important in the development of VHL-
associated tumours. To study this further, among the candidate genes located at 6q we selected ZAC1,
THW and LATS genes, because these genes had been shown to be frequently deleted in many tumours.
Moreover they possess a similar mechanism of inactivation with VHL, since hypermethylation is one of
the inactivating mechanism for VHL-associated tumours.
ZAC1 was isolated by Abdollahi and co-workers (Abdollahi et al. 1997) in a search for expression of
genes lost in an in vitro model of cell transformation. The ZAC1 gene encodes a zinc finger protein, and it
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is an imprinted gene expressed only from the paternal allele with the maternal allele silenced by
promoter region hypermethylation (Arima et al. 2005; Piras et al. 2000).  Imprinted genes are expressed
from one allele according to their parent of origin, and many such genes are essential in mammalian
embryogenesis (Arima et al. 2005).
Functionally the ZAC1 gene product possesses the same characteristic as p53. ZAC1 exhibits tumour
suppressor activity, and inhibits tumour cell proliferation through the induction of both apoptotic cell
death and G1 arrest (Spengler et al. 1997; Varrault et al. 1998). Thus ZAC1 displays antiproliferative
properties through pathways known to be central to the activity of p53. ZAC1 is  located at 6q24-25, a
chromosomal region which has been shown to be deleted in many solid tumours, such as ovarian cancer
(Foulkes et al. 1993), breast cancer (Bilanges et al. 1999), melanoma (Millikin et al. 1991), and
squamous cell carcinoma of head and neck (Koy 2004).
ZAC1 is expressed both in adult and fetal tissues in human pituitary gland, kidney, adrenal gland,
uterus, ovary, mammary gland, liver, whole brain, and spinal cord. In the adult brain, the most intense
signals were observed in the occipital lobe and cerebral cortex (Varrault et al. 1998).  In mouse brain,
high levels of Zac1 expression were determined early in brain development, but in cerebellum, levels of
Zac1 mRNAs were maintained in Purkinje cells (Valente and Auladell 2001; Alam et al. 2005; Ciani et al.
2003;  Valente  et  al.  2005).  An  alteration  in  the  expression  of  the  imprinted  genes  is  one  of  the  most
common changes seen in cancers. Imprinted genes, including ZAC1, function as tumour suppressor
genes suggesting a direct link between loss of imprinting, either by epigenetic changes or chromosomal
deletion, and failure of tumour suppressor mechanisms. Hypermethylation of DNA for the 5’ regulatory
region of ZAC1 was recently detected in several cancer cell lines and primary tumours, and this directly
evoked loss of gene expression (Kamikihara et al. 2005).
Several putative tumour suppressor genes are located in the vicinity of 6q23-24, including the newly
described THW (Human Transmembrane Protein) gene, which has been shown to be expressed in brain,
kidney, liver, pancreas, adrenal glands, uterus and prostate (Hildebrandt et al. 2000).  It is located
between  6q16-23,  and  LOH of  the THW gene has been detected in cell lines derived from melanoma,
pancreas, breast, prostate, cervical and colon cancer (Hildebrandt et al. 2000; Miele et al. 2000).
Recently (Attardi et al. 2000) reported identification of a murine homolog of the THW gene referred to as
PERP. These two genes, THW and PERP share 90% homology in the amino acids in their coding regions.
PERP was found to be expressed in a p53-dependent manner (Hildebrandt et al. 2001)
Another tumour suppressor gene located at 6q24-25 is the LATS1 (Large Tumour Suppressor1)
gene, which has been mapped to chromosome 6q24-25. Loss of heterozygosity for LATS1 has been
observed in ovarian, cervical, and breast cancers. Morinaga and co-workers did not detect any mutation
in breast cancer samples in the LATS1 coding region, but pointed to the possibility that LATS1 may be
inactivated by promoter methylation (Morinaga et al. 2000). LATS1 can suppress tumourigenesis by
regulating cell proliferation and modulating cell survival (St John et al. 1992; Xia et al. 2002).
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AIMS OF THE STUDY
Despite the major role of the VHL gene, a full understanding of mechanism of tumourigenesis of VHL-
associated tumours is  still  lacking. The objective of  this  study was to search for genetic  alterations,  or
other mechanisms in addition to VHL inactivation, which may be important for the development of these
tumours.  In  particular,  the  focus  was  on  identifying  these  events  in  the  sporadic  forms  of  capillary
hemangioblastoma and pheochromocytoma.
Specific aims
With regard to the more detailed objectives, this study sought
? to assess the prevalence of VHL disease in patients suffering from CHB by performing detailed
clinical and other necessary examinations, and further, to study the rate of germ-line mutations
of the VHL gene.
? to characterize DNA copy number changes in addition to those at 3p25-26 which may be of
importance in the development of CHBs by comparative genomic hybridization.
? to study further those chromosomal loci that were frequently affected by DNA copy number
changes and therefore of potential importance in the tumourigenesis of CHBs. Moreover the aim
was to identify candidate genes residing on these particular chromosomal sites.
? to investigate if the same chromosomal areas are affected in PCC.
? to study in detail the role of the ZAC1 gene, located in the chromosomal area identified in the
previous studies.
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MATERIALS AND METHODS
Patients and clinical data (I, II, III, IV, V)
In all, 110 CHB patients were collected from the files of the Department of Neurosurgery, Helsinki
University Central Hospital (HUCH), fulfilling the main three criteria: primary operation for CHBs of the
CNS between 1953 and 1993, histological verification of solid tumour, and CHB ascertained at
histological re-examination by a neuropathologist. The studies were approved by the Ethics Committee of
Helsinki University Central Hospital. These 110 CHB patients consisted of 50 men and 60 women. We
collected all available data and examined records of all hospitals involved for evidence of VHL.  Before the
follow-up examination, a detailed inquiry asking about their illnesses, hospital admissions and operations
was sent to patients. The follow-up time started at the date of the primary operation and ended at death
(49/110 patients) or on August 31, 1998. In 61 of 66 living patients, a detailed clinical examination was
performed in between 1991-1998 to search for signs of VHL disease. This included a family history of
VHL, a physical, neurological and ophthalmologic examination including indirect ophthalmoscopy,
enhanced MRI (1.0 T) of the head and upper cervical spine, and furthermore a CT of the upper abdomen
was performed.
Detailed pedigree analysis  was constructed for 35 CHB patients with their  first  and second degree
relatives, by interviewing the patients or using the files of public registration center (PRC) and the parish
records. These 35 patients with their 471 relatives were linked with the files of the Finnish cancer registry
to search for VHL related neoplasms.
Mutation analysis of VHL
The VHL gene was analysed for germ-line mutations by direct sequencing from all living patients
including 4 cases with clinically clear VHL, and 11 suspect patients,  with CHB and internal  organ cysts
and 25 patients with apparently sporadic CHB. High molecular weight DNA was extracted from peripheral
blood leucocytes using the QiA Amp Blood kit (QiAGEN Ltd., Cambridge UK). The three exons of the VHL
gene were sequenced, including the exon splice sites. The primers and the PCR conditions used were as
described in Chen et al. (1995) with slight modifications. We also used a reverse primer for the exon 1,
SS1,  5  GCGGTAGAGGGGCTTCAGACCGTG-3`.  PCR  products  were  purified  with  the  QiA  Quick  PCR
purification kit (Qiagen, Hilden, Germany), and the sequencing reactions were done using the ABI PRISM
DYE Terminator sequencing kit (Perkin-Elmer Applied Biosystems Division, Foster City, CA), and were
analyzed on the ABI 373 A sequencer. Both strands were sequenced.
These patients and the findings of this study served as the basis for further studies.
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Comparative genomic hybridization (II)
All CHB specimens included in this study had been removed during surgical procedures conducted in the
Department of Neurosurgery, University of Helsinki. In all cases, tumour samples had been fixed in 4%
phosphate buffered formaldehyde immediately after removal, and transported to the Department of
Pathology, University of Helsinki, where the tissue was processed by standard methods and finally
embedded in paraffin. From each tumour the diagnosis had been set as part of routine diagnostic
procedures, but all the cases were re-evaluated for the present study. Altogether we collected 22 tumour
samples from 22 individuals, all were histologically typical CHBs, 18 were from the cerebellum and 4 from
the medulla. Five of the 22 patients had VHL disease, with the diagnosis being based on mutation
analysis and clinical characterization (I). Follow-up information was collected and in some patients new
lesions had been observed. DNA was extracted from the paraffin-embedded sections as described
elsewhere (Miller et al. 1998) with a slight modification. Genomic DNA from peripheral blood lymphocytes
from a healthy donor was also extracted according to standard procedures and used as a reference in the
CGH analysis.  CGH was performed as described previously (el-Rifai et al. 1997; Kallioniemi et al. 1992;
Kallioniemi et al. 1994).
Briefly, tumour and reference DNA were labeled differentially with fluorochrome-conjugated dCTP
and dUTP (DuPont, Boston, MA, USA) and Texas-red-conjugated dCTP and dUTP (DuPont) by nick
translation to obtain fragments ranging from 600 to 2000 base pairs. The hybridization mixture consisting
of equal amounts of tumour and reference DNA was co-hybridized competitively to a normal metaphase
slide prepared from a lymphocyte cell culture of a normal healthy individual. After hybridization and
washes,  the  chromosomes  were  counterstained  with  DAPI  (blue)  and  slides  were  mounted  with  an
antifading medium. The hybridizations were analyzed using an Olympus fluorescence microscope
(Olympus Optical Co. LTD., Japan) and the ISIS digital image analysis system (MetaSystems GmbH,
Altlussheim, Germany) based on an integrated high-sensitivity monochrome charge coupled device
camera  and  automated  CGH  analysis  software.  Three-color  images  (red  for  reference  DNA,  Green  for
tumour  DNA,  and  blue  for  counterstaining)  were  acquired  from  7  -  10  metaphases  per  sample.  An
increase  in  the  DNA  copy  number  was  visualised  by  the  intensity  of  green  (hybridized  tumour  DNA),
whereas a decrease appeared as a red colour (reference DNA). Chromosomal regions were interpreted as
being over-represented when the corresponding ratio exceeded 1.17 (gains) or under-represented
(losses) when the ratio was less than 0.85. Inverse labeling-CGH was performed (tumour DNA labeled
with Texas-red-conjugated and reference DNA with FITC-conjugated dCTP and dUTP) to confirm the
alteration. Imbalances were scored only when present in both hybridizations (CGH and inverse CGH). All
findings were confirmed using a confidence interval of 99% with 1% error probability. CGH is able to
detect losses up to 2 - 5 MB.
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Loss of heterozygosity in capillary hemangioblastoma and
pheochromocytoma (III, IV, V)
Tissue  samples  for  15  capillary  hemangioblastoma  were  collected  from  the  files  of  the  Department  of
Pathology, University of Helsinki (Study III). The set included 11 sporadic and 4 VHL- associated cases.
Nine of the 15 tumours were part of both previous CGH and present LOH studies.
DNA was extracted from histologically characterized capillary hemangioblastomas, from which
adjacent normal tissues were carefully removed, and from the corresponding peripheral blood samples
using standard methods, proteinase-K digestion and phenol /chloroform purification followed by ethanol
precipitation. Tumour and non-tumour DNA were amplified by the polymerase chain reaction (PCR), and
LOH  analysis  was  performed  with  22  micro-satellite  markers  (Research  Genetics,  Inc,  Huntsville,  AL)
covering  chromosome  6q  and  16  spanning  3p  (III).  The  markers  were  selected  to  ensure  a
comprehensive representation of 6q and 3p. The names and the localization of the markers are based on
the unified database (UDB) (http://bioinformatics.weizmann.ac.il/udb). PCR was carried out under the
following conditions: 1x PCR buffer (10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100); 200
mM dGTP, dATP and dTTP; 2 µM dCTP; 0.7 µCi of [33 P] dCTP (3000 Ci/mmol); 10 ng of each primer; 100
ng of genomic DNA template; and 0.5 units of Dynazyme II polymerase (Finnzymes, Espoo, Finland) in a
volume of 10 µl. PCR amplification started with 5 min at 95°C, then 35 cycles for 1 min at 95°C, 1 min at
52-55°C, 1min at 72°C, followed by elongation for 8 min at 72°C. The amplified samples were cooled
down quickly and stored at 4°C. Heat-denatured PCR products were subjected to electrophoresis in 6%
polyacrylamide gel containing 7.7 M urea. After electrophoresis, the gels were transferred to 3mm
Whatman paper, dried and then exposed by autoradiography to X-ray film.
All PCR amplifications with unclear results were repeated. LOH was scored when an allelic band was
absent  or  clearly  reduced  in  density  compared  to  the  corresponding  band  in  normal  DNA  in  repeated
experiments. All  of  the15  cases  were  informative  for  more  than  one  marker  studied  (a  marker  was
considered non-informative when the normal tissue of the patient was homozygous with respect to this
marker) (III).
LOH was studied also in study IV where paraffin-embedded tumour tissue samples from 18 surgically
removed PCCs, fixed in 10% phosphate-buffered formaldehyde were collected from the archives of the
Department of Pathology, Helsinki University Central Hospital. The set included one VHL- associated and
17 sporadic tumours, based on family history and clinical findings (III). All  were located in the adrenal
gland. Nine of the PCC were benign, and another nine were borderline tumours, i.e. tumours without
metastases but having any of the histologically suspicious features, such as more than 5 mitoses/10 high
power fields, confluent tumour necrosis, vascular or capsular invasion (Salmenkivi et al. 2001). Sixteen
of  the  cases  were  women,  and  two  were  men,  with  an  age  range  of  26  –  72  years.   For  statistical
comparisons, student's t-test (Microsoft Excel, Windows 2003) was used.
DNA was extracted from histologically well-characterized paraffin sections, after careful removal of
adjacent normal tissue. Normal DNA was obtained from non-tumourous tissue samples, removed during
the  surgical  procedures  performed  on  these  patients.  DNA  extraction  from  the  tumour  tissue  and  the
corresponding normal tissue samples were performed by standard methods as in the previous LOH study
on CHB (III). Tumour and non-tumour DNA were amplified by the polymerase chain reaction (PCR), and
LOH  analysis  was  performed  with  22  micro-satellite  markers  (Research  Genetics,  Inc,  Huntsville,  AL)
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covering chromosome 6q, the markers were selected to ensure a comprehensive representation of the 6q
region, as described in detail in  study III.
PCR conditions were as indicated above and elsewhere (III, IV). All PCR amplifications with unclear
results  were  repeated.  LOH  was  scored  when  an  allele  band  showed  70%-100%  reduction  in  signal
density in the autoradiogram for one of the alleles of heterozygous tumour DNA, as compared to the
corresponding band in normal DNA. Allelic imbalance (AI) was defined as an alteration constantly seen as
a decrease in signal  density or uneven signal  intensity for a specific  allelic  band in the tumour DNA in
repeated  experiments.  All  of  the  cases  were  informative  for  more  than  one  of  the  markers  studied  (a
microsatellite marker was considered non-informative when the patient was homozygous with respect to
this marker) (IV).
Study V included 8 sporadic and 2 VHL-associated cases as judged/diagnosed by their positive family
history and instrumental investigation results. Previously, both had been part of our LOH studies and
showed LOH at VHL gene area at 3p25-26 (III, IV). Six of these tumours had also been included in our
previous CGH and LOH studies. DNA was extracted from the tumours and the corresponding peripheral
blood samples by standard methods as described above and in the studies (III, IV).
Tumour and non-tumour DNA was amplified by polymerase chain reaction (PCR) and LOH analysis
was performed with 6 microsatellite markers spanning the ZAC gene area, and we also included 3
markers at 6q23-24 which were also part of the previous study and had been reported as a minimal
deleted area (III).   The markers were selected to ensure a comprehensive representation of 6q23-25,
including ZAC specific markers. The names and the localization of the markers are based on the database
UDB (unified data base) as indicated above (III, IV). Similar PCR conditions as described were also used
for  this  study.  All  PCR  amplifications  with  unclear  results  were  repeated.  All  of  the  10  CHBs  were
informative for more than one marker studied (a marker was considered non-informative when the
normal tissue of the patient was homozygous with respect to this marker) (V).
Immunohistochemistry (V)
An immunohistochemical analysis was performed to study ZAC expression in CHBs. Immunostaining of
these tumour tissue sections was performed using the avidin-biotin-peroxide complex method (Ultra
vision, Lab Vision Inc, Fermont, CA, USA). Antigen retrieval was performed by incubation of the slides in
10mM sodium citrate buffer (pH 6.0) for 10 minutes at 95 oC. The rabbit anti-human ZAC1 antiserum (H-
253, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) was used at a 1:100 dilution with overnight
incubation. Normal rabbit serum served as a negative control. Sections from normal cerebellum, pituitary
adenomas and breast carcinomas, all known to express ZAC1, were used as positive controls.
Analysis of promoter methylation (V)
Methylation-specific  PCR  (MSP);  (Herman  et  al.  1996)  was  used  for  the  analysis  of  the  methylation
pattern in the 5’ regulatory region of the imprinted ZAC 1 gene. DNA (1 ?g) from 10 primary CHB, and
also white blood cells from the same patients and 2 specimens from normal brain tissues were exposed
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to bisulphite modification as described previously (Jarmalaite et al. 2003). There was either 14 h
exposure at 50?C with sodium metabisulfite (Sigma) for DNA extracted from paraffin-embedded tissues
or 16 h from frozen specimens. Bisulphite-treated DNA was amplified by PCR with two sets of  primers
designed  for  methylated  (M)  and  unmethylated  (U)  sequences  of ZAC  1 gene 5’ region (GenBank
accession number AL109755, nucleotides 305-439). PCR product was analysed in non-denaturing 7.5%
polyacrylamide gels.  The imprinted status of  the gene was seen as an equivalent MSP product in both
reactions with the primers for M and U sequences. The predominant presence of methylated DNA in MSP
was recorded as a loss of an unmethylated allele. Bisulphite-modified DNA from healthy donors was used
as a negative control and in vitro methylated DNA (SssI methylase, New England BioLabs) as a positive
control for loss of unmethylated allele of ZAC  1.  To  verify  the  sensitivity  of  MSP  analysis,  DNA  from
cancer cell lines (MDA-MB-453 and SKOV-3) with an established degree of methylation in the region
(Abdollahi et al. 2003) was used in our study. Water controls were always included. The specificity of MSP
was tested by direct sequencing of the PCR product from M and U reactions with automated sequencer
(Applied Biosystems) (V).
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RESULTS
Clinical study and VHL mutation analysis (I)
All available clinical data gathered during the median follow-up time of 14 years (range 0.3 - 36 years)
together with a detailed clinical examination 61/110 patients, family history 93/110 patients, detailed
pedigree 35/110 patients,  mutation analysis  40/110 patients,  and linkage to the files of  FCR ( 35 CHB
patients and 471 relatives) made it possible to differentiate three patient groups, ( a ) 14 VHL patients (
b  )  13  patients  with  a  single  CHB  and  visceral  cysts,  but  no  other  VHL  manifestations  and  (  c  )  83
apparently sporadic CHBs. From the unrelated 14 VHL patients discovered, six (43%) had a family history
of  VHL  and  eight  (57%) apparently  had  a  new mutation.  Ten  of  them had  multiple  CHBs  of  the  CNS,
while four had a single CHB only (I)
In 11 of the 14 VHL patients, CHBs of the CNS were the first manifestation of the disease. After the
primary operation 12 of the 14 VHL patients survived at least two years, nine of them died at a median
age of 47 (range 26 - 66) years. RCC was a major cause of mortality, where five died of RCC at a median
age of 49 (range 26 - 66) (I). The linkage of CHB patients and their relatives to the FCR files to identify
VHL-related tumours did not reveal new families. Our analysis revealed a germ-line missense mutation in
exon one (c. 278 G>C and c. 293 A>G) in two of the four VHL patients studied, but none of the other 36
patients (I).
Comparative genomic hybridization in capillary
hemangioblastoma (II)
Of the 22 CHBs studied, chromosomal imbalances were revealed in six tumour samples (5 cerebellar and
1 medullary) by CGH (CGH profiles, Figure 4). Of these, five occurred in sporadic tumours and one in a
tumour  from  a  VHL  patient,  whereas  no  aberrations  were  detected  in  the  remaining  16  tumours.  The
most frequent change was a loss on chromosome 6 seen in five of the 22 (23%) cases, with a minimal
overlapping region at 6q. Additionally losses on chromosome 3 were seen in two of the cases with the
concomitant loss of 6q. In one case, loss on chromosome 8 was detected. No gains were detected in this
study (Figure 5).
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Figure 4. Comparative genomic hybridization profiles of the cases with losses on chromosome 6. The centre line is
the baseline ratio (1.0) and those to the left and right indicate the cut-off values (0.85 and 1.17). (II)
Figure 5. Summary of DNA copy number changes detected by comparative genomic hybridization in 22 capillary
hemangioblastomas. Losses are marked on the left side of the chromosome diagrams. Each line illustrates the affected
region of the chromosome in a single sample.
Loss of heterozygosity in capillary hemangioblastoma and
pheochromocytoma (III, IV, V)
Altogether 15 cases of capillary hemangioblastomas were investigated for LOH in the 6q and 3p regions
with a comprehensive set of microsatellite markers. LOH was observed with at least one marker in all 15
cases.
Allelic losses of 6q were detected in 11 of the 15 tumours (III). Nine of these 11 cases were sporadic
tumours, with the other two being VHL-associated. In the sporadic tumours, the prevalence of 6q LOH
was thus 83%. In the VHL-associated tumours, 6q LOH was seen in 2 out of the 4 tumours included in
the study. Four tumours (T3, T6, T7, and T8) had displayed DNA loss on the long arm of chromosome 6
in the previous CGH study (II); in 3 of those, 6q LOH was also detected. The result allowed us to define a
minimal deleted region that was located between the markers D6S250 and D6S1705. Nine (82%) of the
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informative cases showed LOH with at least one of the markers (D6S250, D6S1703 or D6S1705), (Figure
6). These markers spanned a 3 Mb region on 6q23-24 (III).
With microsatellite markers for 3p, LOH was found in 14 of the 15 CHB cases (III), (Figure 6). The
only case in which 3p LOH could not be detected was a VHL-associated tumour, in which LOH on 6q was
demonstrated with several markers. Allelic losses on 3p were detected in several different regions. LOH
on 3p was detected also in both tumours (T3 and T6) in which 3p and 6q loss had previously been shown
by CGH (II).  Altogether, all 5 tumours negative in the CGH analysis were positive in the LOH analysis.
Moreover, two tumours negative in the CGH analysis (T9 and T10) displayed LOH concomitantly at 6q
and 3p. Four tumours (2 VHL-associated and 2 sporadic) showed LOH only at 3p, and one VHL-associated
tumour at 6q only. Concomitant LOH of 6q and 3p was detected on 10 of the 15 cases. These 10 cases
with LOH detected on both sites included nine sporadic tumours and one VHL-associated tumour (III).
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Figure 6. Illustration of LOH detected with the microsatellite markers D6S1698, 6q, D3S1038, 3p in two tumours
(T) as compared to (B) peripheral blood or normal tissue in CHB. The horizontal lines indicate the alleles, and the
arrows show the location of the missing alleles (III).
In  study  IV,  a  total  of  18  cases  of  PCC were  investigated  for  LOH at  6q  with  a  comprehensive  set  of
microsatellite markers. In particular, we focused on the region 6q23-24, using a total of nine markers. In
the first set of analyses, allele loss of 6q was detected with at least one microsatellite marker in 12 of the
18 tumours.  All  these 12 cases were sporadic PCCs, and the only VHL-associated tumour did not show
LOH. Thus, for the sporadic cases, the prevalence of 6q LOH was somewhat higher 12/17.
For benign PCCs, LOH at 6q was observed in six out of nine cases when the allelic imbalance for the
ZAC  1 specific  markers  in  one  tumour  (T14)  was  taken  into  account.  From  the  tumours  classified  as
borderline, 7/9 exhibited LOH (IV).
Previously, we found a minimal deleted region between markers D6S250 and D6S1705 in CHB (III).
In study IV, 6/18 of the PCCs showed LOH or AI (allelic imbalance) with at least one of the markers for
that region (D6S250, D6S1703 or D6S1705, D6S978) spanning a 3 Mb stretch on 6q23-24. Another
frequently  affected  region  was  6q14,  where  9/18  tumours  showed LOH or  AI  with  at  least  one  of  the
markers studied (D6S1275, D6S1557, D6S280). Four tumours showed LOH in both of these two regions
(IV).
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We further focused the LOH search using six microsatellite markers specific for the ZAC1 gene, one
of the tumour suppressor genes (TSGs) located in 6q23-24 region. For those markers, four of the cases
showed LOH, and two AI. Summing the results obtained with all markers for 6q23-24 region, LOH or AI
was observed in 9/18 of the tumours in this series of PCCs. In addition there were two other regions that
showed  frequent  LOH  (39%),  i.e.  6q12  and  6q21-22.  All  in  all,  taking  into  account  the  whole  set  of
current LOH data, the results revealed that 13 of the PCCs showed allele loss of 6q (IV).
In  study  V,   the  LOH  analysis  of  a  series  of  10  CHBs  carried  out  with  the  microsatellite  markers
D6S308, D6S310, D6S311, D6S978, D6S314, D6S409 (6q23-25) indicated a high overall prevalence of
LOH at the ZAC1 gene region in CHBs 6/10. Five out of 8 sporadic tumours investigated and one of the
two VHL-associated ones exhibited allele loss in the ZAC1 region (V).
Table 4 summarizes the LOH data in combination with our previous CHG results on 6q alterations in
the same CHBs (II, III, IV). With respect to the tumours negative in the present analysis for ZAC 1 LOH,
three (T3, T8, T12) exhibited 6q alterations in the CGH analysis (II), with T3 and T8 showing 6q loss
(III).  In  contrast,  tumour  T14,  a  familial  case,  remained  negative  as  had  been  the  case  in  the  earlier
analyses. In summary, according to our combined data, we identified 6q alterations in all of the sporadic
CHBs  and  in  one  of  the  two  VHL-associated  cases;  i.e.,  altogether,  6q  was  affected  in  10/11  of  the
tumours investigated (V).
Immunohistochemistry for ZAC 1 (V)
A reduced expression of ZAC1 was observed by immunohistochemistry in stromal cells of all CHBs studied
IV. In contrast, endothelial cells of the vessels showed a clear positive staining reaction. ZAC1 was clearly
expressed in Purkinje cells in cerebellar tissue adjacent to the tumour, a finding not previously reported
for  human  brain  tissue.  In  other  cerebellar  tissue,  ZAC1  expression  was  weak  but  still  recognizable
compared to the tumour tissue. A clear positive staining was seen within the tumour cells of
meningiomas, whereas the gliomas exhibited variable ZAC1 expression. Positive signal was also seen in
all high grade (glioblastoma) tumour cells. The staining varied in low grade tumours, with no positivity
detected  in  2  low  grade  astrocytomas.  In  general,  the  IHC  results  for  ZAC1  expression  indicated  a
strongly reduced expression in all 6/6 of the CHB tumours analyzed, which is in accordance with the
results from the LOH and methylation analyses (V).
Promoter methylation analysis of ZAC 1 gene (V)
To determine which allele (i.e. the maternal, imprinted one or the paternal, expressed one) was affected
by  the  allele  losses  found  in  CHB  (V),  the  methylation  status  of  the  5'  region  of  the ZAC1 gene was
investigated using MSP assay. Concurrently to the imprinted status of the gene, MSP analysis detected
both methylated and unmethylated sequences (50% - 50%) in leukocyte DNA from healthy controls and
from patients with CHB. In contrast, a predominance of the methylated, i.e. imprinted, ZAC1 allele was
detected  in  the  majority  of  the  CHBs  9  out  of  10  tumours.  For  these  tumours,  the  MSP  amplification
product  from  the  U  allele  was  negligible;  it  was  incomparably  weaker  than  that  from  leukocyte  DNA,
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indicating  preferential  loss  of  the  transcribed  allele  in  CHB  tumours.  Two  specimens  of  normal  DNA
extracted from cerebellar tissue were also analysed for methylation status and both M and U alleles of the
ZAC promoter region were detected in one of the cerebellar tissue samples, while no reproducible results
were obtained from the other sample (V).
In parallel, the methylation status for ZAC 5’ promoter region in four primary glioma cell lines was
also analysed. One of the glioma cell line exhibited both M and U alleles (i.e., the regular imprinting
status), whereas only the U (transcribed) DNA sequence was present in two cell lines. The fourth cell line
showed the M allele only. In CHBs, an absence of the U sequence for the ZAC1 promoter region was
found to occur concurrently with ZAC allele loss 6/8 (V). When the 6q DNA losses identified in the CGH
study (II) were taken into account, almost all tumours showed this concurrency of allele loss and absence
of an unmethylated ZAC sequence 9/10. The exception was tumour T12, in which no deviation from the
50-50% wild type balance was observed with MSP, and furthermore no LOH was detected in ZAC1 region
(V).
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Table 4.  Summary of LOH data in CHB with six microsatellite markers specific for the ZAC1 gene,
previous LOH data on 6q23-24, data on promoter methylation of ZAC gene by methylation specific PCR
and immunohistochemical (IHC) staining of ZAC protein expression in capillary hemangioblastomas (V),
also includes data from studies II and III.
         Allele  Loss  at 6qCases
LOH on ZAC
markers¹
Previous 6q Loss
data²
Loss of
unmethylated
ZAC allele
IHC staining
VHL-associated
T5 ?
T14         na ?
Sporadic
T3          na
T4 ?
T7 ?
T8 ?
T9        na          na
T10          na
T11          na
T12          na
T13 ?
na,  not analysed ( no DNA or tissue available)
    Positive result
    Negative result
?    Negative for ZAC expression by IHC
¹    Data from study (V)
²    Data from study (II, III)
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DISCUSSION
Since the characterization of VHL disease and, later, after the discovery of the VHL gene, many
investigators have investigated cytogenetic changes, germ-line and somatic mutation, gene promoter
hypermethylation and LOH in order to determine the mutation rate, the loss or inactivation of the gene in
VHL-associated tumours both in familial and sporadic cases.  Moreover, dozens of studies revealed the
functional properties of the VHL protein which helped in understanding the molecular mechanism of the
development not only of VHL-associated tumours, but also how tumours grow in general.
In accordance with the Knudson two-hit model (Knudson 1971), biallelic VHL inactivation is a
common tumourigenic mechanism in the development in both sporadic and familial cases of these
tumours. Individuals with VHL disease carry one wild-type and one inactivated VHL allele. Germ-line
inactivation of the VHL gene initiates VHL hereditary cancer syndromes, and somatic mutations of this
gene have also been linked to the development of both familial and sporadic tumours (Kaelin 2004). In
this thesis work, VHL-associated tumours, particularly capillary hemangioblastomas (CHB) and
pheochromocytomas (PCC) were investigated using an array of various molecular biological techniques
including direct sequencing of the VHL gene, CGH, LOH, promoter hypermethylation and IHC inanattempt
to characterize the mechanism involved in the development of these tumours.
VHL disease and prognosis of hemangioblastomas
Melmon and Rosen proposed the clinical diagnostic criteria for VHL disease (Maher et al. 1991; Melmon
and Rosen 1964; Neumann 1987). In accordance with the classical clinical definition of VHL, our results
(I) revealed three patient groups ( i ) definite VHL (14) cases, where a patient has a family history or a
germ-line mutation of VHL and has developed CHBs of CNS or retina or has suffered other VHL-related
neoplasms; and ( ii ) suspect VHL (13) cases,  patients with no family history who developed one or more
CHB of the CNS or retina and visceral cysts. The rest, the majority, with a single CHB were classified as
sporadic cases (83 cases) several  studies have revealed that the sites of  CHBs differ  between VHL and
non-VHL patients (Filling-Katz et al. 1991; Julow et al. 1994; Maher et al. 1990a; Resche et al. 1993). In
our study, about half of the 14 VHL patients developed CHBs at brain stem or spinal sites, whereas only
5% and 4% of the non-VHL patients had a single CHB in either of these two locations CHB (I).
The average life-expectancy of VHL patients has been reported to be 40 - 50 years (Maher  et  al.
1996) and there is data that RCC is the leading cause of death of VHL patients; in our series after the
primary operation, 12 of the 14 VHL patients survived at least two years, nine of them died at a median
age of 47 (range 26 - 66) years.  In our patients, RCC was noted to be the major cause of mortality, five
died of RCC at median of 49 (range 26 - 66) years (I). Inactivation of the VHL gene has been reported to
cause tumour and tumour-like lesions in more than five different organs and systems; however, organ
involvement can vary considerably among families and has been shown to correlate with the underlying
germ-line alteration (Russell and Theis 2003).
In our mutation analysis, we found a germ-line mutation in exon one in two of the four VHL patients
studied, but in none of the other 36 patients (I). We used a direct sequencing method which is known to
detect  about  75%  of VHL mutations (Brauch et al. 1995b; Zbar et al. 1996), both mutations were
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missense mutations known to be associated with PCCs (Chen et al. 1996), which were identified in the
family of one VHL patient.  However, clinically we observed retinal CHBs in eight patients (5/8 bilateral),
RCC in 10 patients which in six cases were bilateral,  and PCCs in two patients (one bilateral),  visceral
cysts in a minority of cases (I). In accordance with our result,  (Rasmussen et al. 2006) used direct
sequencing  to identify the germ-line mutation in 5/6 of definite VHL cases but none in the possible
(suspect) VHL and sporadic cases.
Recently, by using more sensitive methods, it was possible to detect a 100% inactivation rate in
familial cases of CHB (Zbar et al. 1999). However, using those same methods, only up to 20 - 50% of
sporadic CHBs were shown to be inactivated in the VHL gene area (Gläsker et al. 2001). These results
warrant further study, and hopefully will encourage other research teams to seek for other chromosomal
sites which may be of interest in the development of sporadic cases in particular and CHBs in general.
DNA copy number changes in capillary hemangioblastoma
and VHL-associated tumours
To seek and identify potentially new chromosomal areas that may be important in helping to understand
the molecular mechanism behind the development of these tumours a CGH study was performed. The
study revealed chromosomal imbalances in 6 tumour samples; no aberrations could be detected in 16
tumours. The most frequently detected loss was the loss on chromosomal arm 6q, seen in 5 (23%) of the
22 CHBs. Among those 6 cases with chromosomal imbalance, 5 were classified as sporadic and one was a
VHL patient (II). The study also revealed losses of chromosome 3 in two of the cases, but concomitantly
with the loss of 6q (II). When i started this work 6q losses was not known to be related with CHBs,
but, later in accordance with our results, in the study by Sprenger where specifically sporadic CHBs were
investigated by CGH, a high rate (70%) of chromosome 3 loss was found, but frequent chromosomal
aberrations including those on chromosome 6 (50%), were also detected (Sprenger et al. 2001).
Additionally Gijtenbeek studied sixteen sporadic and seven familial CHBs where loss of chromosome 3 in
69% and chromosome 6 losses were identified in 44% of the tumours studied (Gijtenbeek et al. 2002).
Interestingly, other VHL-associated tumours have also been revealed losses on chromosomal arm
6q. Dannenberg studied 29 PCCs by CGH and reported among several other changes that there was 34%
6q loss in 34 % of of cases. Similarly, they reported loss of 3p in 31% of the tumours (Dannenberg et al.
2000). Other VHL-associated tumours, particularly RCCs, have also been studied by CGH and by other
cytogenetic studies; where losses of 6q have been reported in 14–28% of the cases (Bissig et al. 1999;
Gronwald et al. 1997; Maloney et al. 1991). However  loss  of  6q  is  not  explicitly  related  only  to  VHL-
associated tumours, loss of 6q has also been reported in several benign and malignant CNS tumours,
including meningioma (Khan et al. 1998), ependymoma (Readon et al. 1999), glioblastoma (Kim et al.
1995) and some other gliomas (Kros et al. 1999).
In  our  series,  it  was  observed  that  loss  of  6q  did  not  affect  the  clinical  behaviour  of  the
tumour (II). A new CHB developed only in one of the patient with a tumour harbouring a 6q loss, and this
patient had VHL disease. The other 4 cases with loss of 6q were sporadic tumours, and no recurrences
have  occurred  in  these  patients  during  the  follow-up  period.  It  may  be  too  early  to  draw  any  firm
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conclusion, however, according to the findings of this study, loss of 6q in CHB does not appear to be an
indicator of an aggressive phenotype. Instead, it seems to point to an inactivation of a so-far unidentified
gene located at 6q that may be involved in the tumourigenesis of VHL-associated tumours.
Additionally,  we found chromosome 3 loss in two of  the 22 tumours (II),  CGH detects losses in a
range  of  2  -  5  Mb,  thus  it  may  not  sensitive  enough  to  detect  small  losses  (Kallioniemi  et  al.  1992;
Kallioniemi et al. 1994).  The VHL tumour suppressor gene has been mapped at 3p25 p26,  and  the
initiation of tumourigenesis is believed to occur as a result of mutational inactivation of both alleles of the
VHL gene. Interestingly, different previous studies related to sporadic CHB showed loss or inactivation of
the VHL gene up to 27 - 52% (Bender et al. 2000; Kanno et al. 1994; Oberstrass et al. 1996; Prowse et
al. 1997; Lee et al. 1998) also suggesting the existence of other inactivating or tumourigenic
mechanisms. Thus, our result provides support for the belief that some other chromosomal regions,
probably 6q, are involved in the tumourigenesis of CHBs.
This new insight is in accordance with the growing new knowledge and hypothesis for the
development of VHL-associated sporadic tumours.  Since inactivation of VHL gene predisposed patients to
CHBs, clear cell RCC and PCCs, a close relationship between the tumourigenesis of these tumours is to be
expected. The brief summary of the frequencies of aberrations detected in these three tumour types, as
indicated by the above findings from recent CGH and other studies highlights the importance of both
chromosome 3 and 6 losses, and suggests that the three VHL-associated tumour types may possess a
similar pathway of tumourigenesis.
Loss of heterozygosity in capillary hemangioblastoma and
pheochromocytoma
In the studies following the CGH findings, a series of LOH studies were performed in both CHBs and PCCs
separately. Detection of allelic loss on a specific chromosomal region in a given tumour type is one
important way to discover regions of TSG important for tumour pathogenesis.  The study of 15 CHBs for
LOH on chromosome 6q and 3p (III), revealed LOH at 6q in 73% of the cases. From these tumours, the
majority (82%) occurred in sporadic cases, in VHL cases, the frequency was 50% (III).
As  the  studies  of  Morita  revealed  on  RCC  (Morita  et  al.  1991),  we  also  observed  LOH  over  large
regions of the chromosomal arm of 3p, At 3p LOH was detected in 93% of tumours and 67% of the cases
showed 6q and 3p losses concurrently (III). As in the CHBs, the study of the PCC (IV) also revealed LOH
on 13/18 (72%) of PCCs examined, including tumours classified as benign or borderline, showing allele
loss at 6q (IV). Similar to the situation with the CHBs, which were characterised by a minimal deleted
region at 6q 23 - 24, it was also able to characterize two commonly affected regions at 6q in PCC. One of
them was located at 6q14, where (9/18) tumours displayed LOH or allelic imbalances, and another at
6q23-24 where, when taking also the ZAC1 specific markers into account, 9 out of 18  PCCs showed LOH
or AI.
As described above, two genetic events or "hits" are thought to occur to the two alleles of the TSG;
the  first  hit  being  a  germ-line  mutation,  and  the  "second  hit"  usually  a  deletion  in  the  somatic  cells
(Knudson 1971; Knudson 1995), and the impact of the size of this deletion is thought to be critical since
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other TSGs are located nearby. Following the two hit theory, Gläsker et al. (Gläsker 2005) mapped the
deletion size of the predicted somatic deletion of the "second hit" from 16 different VHL-associated
lesions taken from the same patient. It was claimed that the deletion size was highly variable, ranging
from short deletions around the VHL gene to a complete loss of chromosome 3. The size of the somatic
deletion did not correlate with the site of the germ-line mutation, the affected organ, or the type or
biological behavior of the tumour, even preneoplastic cystic structures may harbor entire loss of
chromosome 3, suggesting that loss of VHL gene function alone was not immediately causative for
neoplastic growth (Gläsker 2005).
In this study, concomitant LOH on 6q and 3p was observed in the majority (67%) of the CHBs (III).
This observation was even more common in sporadic CHBs, where 82% of the sporadic CHBs displayed
LOH on both 3p and 6q. This suggests that tumourigenesis in most CHBs and in the sporadic cases in
particular, may be dependent on the inactivation of genes located in both 6q and 3p. In support of these
results, Gijtenbeek et al. (2002) reported their findings suggesting that the molecular mechanisms
underlying sporadic and familial hemangioblastomas may be different.  In their study, 3p loss was more
common in sporadic CHBs than previously reported, pointing to a role in the tumourigenesis of sporadic
tumours. Thus, our CGH and LOH results combined with the above mentioned studies, suggest that 3p in
addition to 6q is a characteristic site of allelic loss in CHBs.
As indicated above, in addition to CHBs, loss of 6q has also been observed in most other tumour
types occurring in VHL disease, including sporadic and VHL-associated RCC (Alimov et al. 2000; Bissig et
al. 1999; Morita et al. 1991; Thrash-Bingham et al. 1995), PCCs (Dannenberg et al. 2000), endocrine
pancreatic tumours (Barghorn et al. 2001) where losses of 6q are involved in the malignant progression
of sporadic endocrine pancreatic tumours, as well as in other tumour types (Acevedo et al. 2002; Hansen
et al. 2002; Miyakawa et al. 2000). However, since CHBs are classified as benign tumours (Gläsker
2005),  these  findings  in  our  CHB series  may  suggest  that  6q  allelic  losses  are  early  events  in  tumour
development, and accordingly no differences in clinical behaviour would be expected to be associated
with LOH on 6q (III). Moreover, three of the four VHL-associated tumours were located in the medulla,
and in one of these LOH of 6q was detected, showing that allelic losses at 6q are not specific to cerebellar
CHBs (III). Some work, (Theile et al. 1996; Wan et al. 1999) has provided convincing evidence for the
importance of 6q in the process of tumourigenicity, i.e. the transfer of a normal chromosome 6 into
breast and ovarian carcinoma cell lines suppressed their tumourigenic potential. Similar to our study,
these  above  authors  analyzed  the  cell  lines  for  the  occurrence  of  LOH,  and  they  indicated  the  region
6q23-25 as the area for a putative TSG.
Interestingly, some studies not only showed 6q LOH in general, but also a minimal deleted region at
6q14  and  6q23-24,  suggesting  that  the  genes  located  in  this  area  are  likely  to  contribute  to  the
pathogenesis and  malignant  behavior of these tumours (Barghorn et al. 2001; Foulkes et al. 1993a). In
accordance with these findings, we also observed minimal deleted regions both at 6q14 and 6q23-24 in
our series of PCC tumours (IV). Moreover, Tibiletti et al. showed 6q abnormalities in benign, borderline,
and malignant tumours of ovarian surface epithelium. The authors suggest that, at least in part of the
cases, some of the borderline tumours may have arisen from benign tumours, and, again, some
malignant cases may have evolved from tumours of borderline malignancy (Tibiletti et al. 2001). They
further suggested that the genes located on 6q may play a role in the early events of  tumourigenesis,
which is in good agreement with our findings in CHBs (III).
DISCUSSION
____________________________________________________________________________________
48
In agreement with the result of the above study, we found a slightly higher frequency (7/9) of allele
loss at 6q in borderline in comparison with benign (6/9) PCC tumours (IV). In addition, the LOH positive
tumours tended to be somewhat larger in size, even though, no clinical differences were observed (IV),
similar to the results of ovarian tumours (Tibiletti et al. 2001). In summary, these various sets of data
indicate that these regions may contain one or more of the TSGs involved in the tumourigenesis of PCCs l
as has been proposed for some other tumour types. Nevertheless, it remains an open question whether
the same gene(s) may be involved in each tumour type.
Loss of heterozygosity, immunohistochemistry and promoter
hypermethylation at ZAC1 gene
In the above investigations, a series of studies on VHL-associated tumours, in particular CHBs and PCCs
were carried out (I - IV). These studies revealed frequent genetic alterations on chromosome 6q
including the candidate TSG LOT-1 gene, also called ZAC1, located at 6q24 -25. Further, we focused our
attention on clarifying the importance of the functional loss of this suppressor gene in the tumourigenesis
of CHBs.
Promoter hypermethylation of tumour suppressor genes is recognized as an alternative to genetic
alterations in disrupting gene function (Belinsky 2004; Feinberg et al. 2006; Jones and Laird 1999).
Hypermethylation of DNA in the 5’ regulatory region of ZAC1 was also detected in several cancer cell
lines  and  primary  tumours,  and  it  directly  caused  loss  of  gene  expression  (Cvetkovic  et  al.  2004;
Kamikihara et al. 2005). In our study, a methylated ZAC1 promoter sequence was predominant in the
tumours; i.e. we detected only the methylated sequence in the ZAC1 promoter in all but one (9/10) of
the CHBs.
During tumour suppression, genetic and epigenetic mechanisms may act in parallel, (Jones and Laird
1999). In the case of an imprinted tumour suppressor gene such as ZAC1, one allele is not expressed due
to imprinting, and therefore an alteration - genetic or epigenetic - of the other, expressed allele is
sufficient to achieve gene inactivation. In accordance with such a situation, in our LOH study the majority
(5/8) of the sporadic CHBs were positive for ZAC1 LOH, and one of the two familial cases also exhibited
ZAC1 LOH (V). By combining data from our earlier studies (I - IV) on the same set of CHBs, we found
that the rest  of  the studied 10 tumours either exhibited LOH at 6q23-24, or were shown to display 6q
CGH loss, with the exception one tumour. Thus our result showed a predominance of the methylated
promoter allele of ZAC1 in a series of capillary hemangioblastomas and concurrent LOH or 6q loss in all
but one of the CHBs investigated (V).
Loss of expressed allele has also been reported in glioma, another CNS tumour. Selective loss (6/6
cases  of  LOH)  of  paternally  expressed  alleles  on  chromosome  19q  has  been  described  in
oligodendrogliomas (Sanson et al. 2002). We included four glioma cell lines in our analysis of ZAC1
methylation. One of them showed loss of the unmethylated allele, two exhibited loss of imprinting with
only the unmethylated ZAC1 promoter sequence being present, and one was a wild type with both types
of ZAC1 alleles detected. In contrast to the situation with CHBs, in gliomas, ZAC1 alterations appeared to
be random, possibly influenced by additional factors. Our findings suggest that ZAC1 has different
functions in the pathogenesis of CHBs and gliomas (V).
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Our IHC analysis detected limited expression of ZAC1 in adult brain tissues, and a weak expression
was found in cerebellum but ZAC1 was strongly expressed in Purkinje cells (V). Accordingly, Varrault et
al, reported weak expression of ZAC in different brain areas including cerebellum (Varrault et al. 1998).
However, expression of Zac1 in Purkinje cells was observed in the brains of adult mice (Ciani et al. 2003).
Interestingly, a similar pattern of expression has also been shown for VHL. Zac1 is abundant in Purkinje
cells  but,  only  a  weak  staining  was  observed  in  the  molecular  layer  of  the  cerebellum (Maartje and
Gerard 1996; Varrault et al. 2006). As previously indicated, loss of VHL functions leads to stabilization of
HIF, and overproduction of HIF-inducible proteins, and this promotes tumour vascularisation (Maxwell
2005). Recently, significant HIF-1?-dependent suppression of Zac1 production was detected in mouse
fibroblasts exposed to nickel or hypoxia, while in HIF-1? deficient cells, Zac1 expression was totally lost
(Salnikow et al. 2003), which when combined with data from the present study may point to a possible
involvement of ZAC1 in HIF-controlled cellular responses to hypoxia, or in the VHL/HIF-associated
pathway to carcinogenesis. In summary, the results of the five studies included in this PhD thesis and
other studies described above point to the involvement of not only one particular gene, VHL, but to roles
for other TSGs in CHB and PCC, two VHL-associated tumours. This work points to the presence of other
pathways that may play an important role in tumourigenesis of VHL-associated tumours, particularly in
sporadic cases where there is limited or no VHL gene inactivation.
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CONCLUSIONS
These studies were intended to clarify the mechanism of tumourigenesis of VHL-associated tumours.
Initially, 120 consecutive patients operated for capillary hemangioblastoma were collected, and, after
clinical and radiological examination, 14 definitely VHL patients, 13 suspect, and 93 apparently sporadic
cases were identified. In VHL gene sequence analysis, we found a VHL germline mutation in two out of
four familial  cases,  but none of  the suspect or sporadic cases displayed any mutations.  Our result  and
other reports on sporadic CHBs point to the involvement of other genes in the development of these
tumours.
The  screening  of  the  whole  chromosomal  area  of  22  sporadic  and  familial  cases  of  CHBs  by  CGH
revealed 27% DNA copy number losses. In the six cases with DNA copy number changes, five occurred in
sporadic cases with the other being a VHL patient, in these patients, the most recurrent finding was loss
of chromosomal arm 6q (23%). Apparently, loss of 6q may be important for the development of sporadic
tumours, and may possibly also occur in some of familial cases.
A LOH analysis of 15 CHBs of both sporadic and familial origin revealed that a majority of the cases
displayed 6q LOH; most of the cases were sporadic, only two of them were familial. Importantly this work
characterized a minimal deleted region at 6q23 -24 apparently involved in CHB development. However,
clinically no tumour-characteristic changes could be exhibited. This result provided a new insight into our
understanding of the mechanism behind the development of these tumours, and opened a new direction
for the further studies included in this work.
The search for other regions of importance not only revealed losses in CHBs but also in PCCs, where
again a very high frequency of 6q LOH was discovered. Moreover, similar to our findings in CHBs, PCCs
also exhibited a high frequency (50%) of LOH at 6q23-24 area. On the other hand, both borderline and
benign tumours of PCCs showed a high frequency of LOH at 6q, thus 6q is probably not a characteristic
differentiative marker for borderline and benign tumours, since both types showed a similarly high
frequency of LOH.
We hypothesized that the ZAC1 gene might be involved in CHB formation based on the observed
high frequency of inactivation occurring either via chromosomal or allelic deletions at this candidate TSG
gene area of  6q23-24. In accordance with the imprinted gene status and thus an initial  transcriptional
silencing of maternal allele characteristics, the final study of the present series revealed a predominance
of the methylated ZAC1 sequence in 90% of CHBs studied. In parallel, 60% of LOH was exhibited in ZAC
gene area. In agreement with the above result, immunohistochemistry also revealed a strongly reduced
expression of ZAC1 in CHBs.
Finally, as an overall conclusion, the current observations strongly propose involvement of 6q losses
in the tumourigenesis of VHL-associated tumours in both PCCs and CHBs. Moreover, the work
demonstrated the inactivation of the imprinted ZAC1 tumour suppressor gene through loss of the
expressed allele, a novel finding particularly in CHBs. Collectively the studies included in this thesis work
highlight the importance of the ZAC1 gene in the tumourigenesis of sporadic CHBs. These data also imply
that the two types of VHL-associated tumours may share other common molecular features in their
tumourigenesis, in addition to VHL gene mutations.
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